

Lucas G. Hill, PharmD, FCCP

10062 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261
irc.pitt.edu | HillPharmD@Pitt.edu | 412-648-0359

Education & Training

Clinical Pharmacy Residency <i>University of Pittsburgh Medical Center (UPMC)</i>	2013–2015
Faculty Development Fellowship <i>University of Pittsburgh School of Medicine</i>	2013–2015
Doctor of Pharmacy <i>University of Missouri–Kansas City School of Pharmacy</i>	2006–2013

Professional Appointments

Associate Professor of Pharmacy and Therapeutics Executive Director, Implementation and Research Center for Healthy Communities (IRC) <i>University of Pittsburgh (Pitt) School of Pharmacy</i>	2024–Present
Adjunct Associate Professor of Pharmacy Practice Clinical Associate Professor of Pharmacy Practice Director, Pharmacy Addictions Research & Medicine (PhARM) Program Clinical Assistant Professor of Pharmacy Practice <i>The University of Texas at Austin (UT) College of Pharmacy</i>	2024–Present 2021–2024 2020–2024 2015–2021
Clinical Pharmacist <i>CommUnityCare Federally Qualified Health Centers</i>	2015–2019

Licensure, Certification, & Development

Pharmacist: Pennsylvania State Board of Pharmacy (RP447805)	2013–Present
Big Proposal Bootcamp: Pitt Research	2026
Advanced Faculty Leadership Academy: Pitt Office of Academic Career Development	2025
Guided Grant Writing Program: American Association of Colleges of Pharmacy	2025
Mentoring Academy Credential: Pitt University Center for Teaching and Learning	2025
Pharmacist: Texas State Board of Pharmacy (57209)	2015–2025
Preceptor: Texas State Board of Pharmacy	2015–2025
Ambulatory Care Pharmacist: Board of Pharmacy Specialties	2016–2023
Pharmacotherapy Specialist: Board of Pharmacy Specialties	2014–2021
Grant Writers' Seminars and Workshops: Write Winning Grant Proposals – NIH	2020
Buprenorphine Waiver Training: Providers Clinical Support System	2020
OSCEology Workshop: University of Toronto Leslie Dan Faculty of Pharmacy	2020
Mariner Project: American Association of Colleges of Pharmacy	2018
TeamSTEPPS Master Trainer: Agency for Healthcare Research & Quality	2016
Injectables: Pennsylvania State Board of Pharmacy	2013–2016

Awards & Honors

National

American College of Clinical Pharmacy: Fellow	2023
American College of Clinical Pharmacy: New Educator Award	2021
American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year	2021
American Pharmacists Association: Generation Rx Award of Excellence	2020
American College of Clinical Pharmacy AmCare PRN: Outstanding Paper of the Year	2019
American Society of Health-System Pharmacists: CEO's Award for Courageous Service	2018
Phi Lambda Sigma Pharmacy Leadership Society: Faculty Inductee	2017

Regional

Austin Under 40 Awards: Finalist in Medicine & Healthcare	2021
Austin Under 40 Awards: Finalist in Medicine & Healthcare	2020
Texas Pharmacy Association: Generation Rx Champion Award	2018

Local

UT College of Pharmacy: 10 Most Impactful Faculty	2022
UT College of Pharmacy: Outstanding Faculty Advisor	2019
UT School of Undergraduate Studies: Distinguished University Lecturer	2018
UT College of Pharmacy: 10 Most Impactful Faculty	2018
UT College of Pharmacy: William Arlyn Kloesel Outstanding APPE Preceptor	2017
UT College of Pharmacy: ATW Regional Outstanding APPE Preceptor	2017
UT College of Pharmacy: Outstanding IPPE Preceptor	2017
UT College of Pharmacy: Phi Lambda Sigma Pharmacy Leadership Society	2017

Fellowships

UT College of Pharmacy: Fellow of the Eckerd Professorship	2024
UT College of Pharmacy: Bergen Brunswig Corporation Centennial Fellow	2021–2024
UT College of Pharmacy: Alumni Centennial Fellow – Advisor	2019–2020
UT College of Pharmacy: Alumni Centennial Fellow – Preceptor	2017–2018

Grants, Contracts, & Consulting

Ongoing

Physical Health Centers of Excellence Auditing Standardization (\$560,000)

- Role: Principal Investigator
- Sponsor: Pennsylvania's Medicaid Managed Care Organizations
- Funding Period: 2/1/2026–1/31/2028

Lincoln University Screening, Brief Intervention, and Referral to Treatment (\$464,277)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 9/1/2024–9/30/2027 [role began 12/1/2024]

Centers of Excellence for Opioid Use Disorder: Care Management Technical Assistance (\$2,192,927)

- Role: Principal Investigator
- Sponsor: Pennsylvania Department of Human Services
- Funding Period: 7/1/2025–6/30/2027

Project Lifeline National Rollout (\$900,000)

- Role: Principal Investigator
- Sponsor: National Association of Chain Drug Stores Foundation
- Funding Period: 1/1/2023–6/30/2027 [role began 12/1/2024]

Carbon County Drug Treatment Court Enhancement (\$193,013)

- Role: Principal Investigator
- Sponsor: Pennsylvania Commission on Crime and Delinquency
- Funding Period: 12/1/2024–9/30/2026

Pediatric Complex Care Resource Centers Caregiver Curriculum (\$6,584,739)

- Role: Co-Principal Investigator
- Sponsor: Pennsylvania Department of Human Services
- Funding Period: 11/1/2024–6/30/2026 [role began 12/1/2024]

Improving Opioid Stewardship and Access to Harm Reduction Services through Allegheny County Community Pharmacies (\$210,200)

- Role / Effort: Co-Investigator / 5%
- PI: Joni Carroll, University of Pittsburgh
- Sponsor: Allegheny County
- Funding Period: 4/1/2025–6/30/2026

Completed

Centers of Excellence for Opioid Use Disorder: Care Management Technical Assistance (\$1,080,018)

- Role: Co-Principal Investigator
- Sponsor: Pennsylvania Department of Human Services
- Funding Period: 7/1/2024–6/30/2025 [role began 12/1/2024]

Recovery Coach Workforce Education Series (\$149,801)

- Role: Principal Investigator
- Sponsor: Pennsylvania Department of Labor and Industry
- Funding Period: 8/1/2024–6/30/2025 [role began 12/1/2024]

Controlled Substance Prescribing & Linkage to Treatment Curriculum (\$499,162)

- Role / Effort: Co-Investigator / 10%
- PI: Lisa Sipusic, University of Pittsburgh
- Sponsor: Pennsylvania Department of Health
- Funding Period: 9/1/2023–3/31/2025 [role began 12/1/2024]

Creation of a Multi-Stakeholder Practice Guideline to Improve Access to Medications for Opioid Use Disorder in Community Pharmacies (\$572,278)

- Role / Amount: Co-Investigator / \$28,872
- PI: Tyler Varisco, University of Houston
- Sponsor: Foundation for Opioid Response Efforts
- Funding Period: 4/1/2023–3/31/2025

Texas Targeted Opioid Response – Educational Task Force (\$4,942,560)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 9/01/2024–8/31/2026 [role ended 11/30/2024]

Empowering Clinicians to Prevent Opioid-Related Harms and Treat Opioid Use Disorder: An Academic Detailing Intervention for Prescribers in Austin, Texas (\$375,000)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 9/30/2023–01/31/2026 [role ended 11/30/2024]

Texas Targeted Opioid Response – PhARM Program Special Projects (\$34,045,430)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 5/1/2019–8/31/2024

Overdose Prevention Education Curriculum and Toolkit (\$120,000)

- Role: Principal Investigator
- Sponsor: Texas Education Agency
- Funding Period: 5/15/2024–8/31/2024

SHIFTovation Award – Operation Naloxone (\$44,000)

- Role: Principal Investigator
- Sponsor: UT University Health Services
- Funding Period: 2/7/2020–08/31/2023

Center for Health Statistics – Drug Dashboard Enhancement (\$102,500)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 4/1/2021–8/31/2022

A Statewide Needs Assessment to Identify Opportunities to Improve Access to Medications for Opioid Use Disorder through Mobile Service Provision (\$162,579)

- Role / Amount: Co-Investigator / \$30,000
- PI: Jennifer Sharpe Potter, UT Health San Antonio
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 6/1/2022–8/31/2022

Preparing Health Professions Learners for Dual Identity Development Using the Interprofessional Socialization Framework (\$4,000)

- Role: Co-Investigator
- PI: Veronica Young, UT Center for Health Interprofessional Practice and Education
- Sponsor: UT Center for Teaching and Learning
- Funding Period: 6/1/2022–8/31/2022

Evaluation of Naloxone Counseling Provided by Community Pharmacists (\$3,995)

- Role: Co-Investigator
- PI: Kirk Evoy, UT College of Pharmacy
- Sponsor: UT Health San Antonio Center for Community Service Learning
- Funding Period: 2019–2020

Texas Targeted Opioid Response – Operation Naloxone (\$2,587,149)

- Role: Principal Investigator
- Sponsor: Substance Abuse and Mental Health Services Administration
- Funding Period: 7/1/2017–4/30/2019

Operation Naloxone – Community Overdose Prevention Training (\$28,000)

- Role: Co-Investigator
- PI: Kirk Evoy, UT College of Pharmacy
- Sponsor: UT Health San Antonio Center for Community Service Learning
- Funding Period: 2018–2019

Interprofessional Naloxone Training for Student Faculty Collaborative Practice (\$1,225)

- Role: Co-Investigator
- PI: Kirk Evoy, UT College of Pharmacy
- Sponsor: UT Health San Antonio Center for Community Service Learning
- Funding Period: 2018–2019

Operation Naloxone Service Learning Expansion (\$3,344)

- Role: Co-Investigator
- PI: Kirk Evoy, UT College of Pharmacy
- Sponsor: UT Health San Antonio Center for Community Service Learning
- Funding Period: 2018–2019

Operation Naloxone – Interprofessional Overdose Prevention Service Learning (\$4,000)

- Role: Co-Investigator
- PI: Kirk Evoy, UT College of Pharmacy
- Sponsor: UT Health San Antonio Center for Community Service Learning
- Funding Period: 2017–2018

Consultant

U.S. Department of Justice Civil Rights Unit: Litigate Consultant	2023–Present
Health Management Associates: Compassionate Overdose Response Summit Panelist	2024
Foundation for Opioid Response Efforts: Pharmacy Program Advisory Committee	2022
UT Center for Health Communication: Texas Prescription Monitoring Program	2017–2022
American Academy of Addiction Psychiatry: Opioid Response Network	2019–2021
Hazelden Betty Ford Foundation: Innovation in Medical Education on Addiction	2021
American Academy of Addiction Psychiatry: Opioid Response Network Expert	2019–2021
American Academy of Addiction Psychiatry: Clinical Skills for Healthcare Providers	2019–2020
The University of Texas at El Paso: Opioid Overdose Prevention Program	2019

Peer-Reviewed Journal Articles

Pending

60. Hairgrove A, Nichola MA, Williams J, **Hill LG**, Loera LJ, Bosworth JR, Raymond L, Duncan Cance J. (In revisions). Continuing education to improve clinician knowledge, attitudes, and practice behaviors related to opioid use disorder. *J Contin Educ Health Prof.*
59. Erickson E, Kane H, Garcia SA, Hinnant L, Rabre A, **Hill LG**, Loera LJ, Temblador A, *Duncan Cance J. (In revisions). “Leaving the decision step to me:” School naloxone policies developed and implemented by district and school nurses. *Subst Use Addctn J.*
58. Sisson LN, Rousch RS, **Hill LG**, *Zagorski CM*, Triage T, Rouhani S, Owczarzak J, Sherman SG, *Schneider KE. (In revisions). “If you’ve ever experienced it, you’d feel differently”: Exploring willingness and skepticism towards using higher dose naloxone products among people who use drugs in Maryland. *Addiction.*
57. *Torrez SB*, Evoy KE, **Hill LG**, Lawson KE, Reveles KR, *Loera LJ. (Accepted). Increasing buprenorphine and naloxone access in Texas community pharmacies through an academic detailing intervention. *Subst Use Addctn J.*

Published

56. Hendy LE, **Hill LG**, Olguin A, Barrett E, Jimes C, Coffey MJ, *Lira MC. (2025). Pharmacy barriers to receiving buprenorphine among patients in telemedicine addiction treatment. *JAMA Netw Open.* 8(8): e2527418. DOI: 10.1001/jamanetworkopen.2025.27418.
55. *Folan DM*, **Hill LG**, *Berenbrok LA. (2025). Encouraging OTC naloxone accessibility across the United States. *J Am Pharm Assoc.* DOI: 10.1016/j.japh.2025.102464.
54. Varisco TJ, Thornton D, Hussain T, Fish H, Bolin J, Dadiomov D, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Bratberg J, DiPaula B, ***Hill LG**. (2025). Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-ODU Expert Panel. *Drug Alcohol Depend Rep.* 16:100360. DOI: 10.1016/j.dadr.2025.100360.

53. *McCullough HP*, Kane H, Duncan Cance J, Tatum C, Loera LJ, Kmetz L, ***Hill LG**. (2025). Wound care practices among people who inject drugs in Austin, Texas. *Subst Use Addctn J*. 46(4):1019-1026. DOI: 10.1177/29767342251334203.
52. ***Hill LG**. (2025). Redefining opioid stewardship. *J Am Coll Clin Pharm*. 8:168-170. DOI: 10.1002/jac5.70002.
51. Loera LJ, *Lines J*, *Mayberry S*, *Hilzendager S*, Ferguson A, ***Hill LG**. (2025). Over-the-counter naloxone and non-prescription syringe availability in community pharmacies. *JAMA Netw Open*. 8(2):e2458095. DOI: 10.1001/jamanetworkopen.2024.58095.
50. **Varisco TJ*, Fish H, Bolin J, Dadiomov D, **Hill LG**, Essien E, Wanat MA, Ginsburg D, Waggener J, Thornton D. (2024). The pharmacy access to resources and medication for opioid use disorder (PhARM-OUD) guideline: A joint consensus practice guideline from the National Association of Boards of Pharmacy and the National Community Pharmacists Association. DOI: 10.52713/PhARM-OUD.
49. **Russell E*, Hawk M, Neale J, Bennet A, Davis C, **Hill LG**, Winograd R, Kestner L, Lieberman A, Bell A, Santamour T, Murray S, Schneider KE, Walley AY, Jones TS. (2024). A call for compassionate overdose response as the standard of care. *Int J Drug Policy*. 133:104587. DOI: 10.1016/j.drugpo.2024.104587.
48. **Varisco TJ*, Fish H, Bolin J, Dadiomov D, **Hill LG**, Essien E, Wanat MA, Ginsburg D, Waggener J, Yazdanfard S, Song J, Chi W, Thornton D. (2024). Protocol for the development of a consensus practice guideline to address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy. *Arch Pub Health*. 82(1):58. DOI: 10.1186/s13690-024-01287-4.
47. Light AE, Green TC, Freeman PR, Burns AL, Sanaty Zadeh P, ***Hill LG**. (2024). Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: Results from a national sample. *Subst Use Addctn J*. 45(2):211-221. DOI: 10.1177/29767342231215178.
46. Jarrett JB, Bratberg JP, Burns AL, Cochran G, DiPaula BA, Dopp AL, Elmes A, Green TC, **Hill LG**, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu L, **Bart G*. (2023). Research priorities for expansion of opioid use disorder treatment in the community pharmacy. *Subst Abus*. 44(4):264-276. DOI: 10.1177/08897077231203849.
45. *Zagorski CM*, Hosey R, Moraff C, Ferguson A, *Figgatt M*, Aronowitz S, Stahl N, **Hill LG**, McElligott Z, **Dasgupta N*. (2023). Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context. *Harm Reduct J*. 20:141. DOI: 10.1186/s12954-023-00879-7.
44. *Zalmai R*, ***Hill LG**, Loera LJ, *Mosgrove Q*, Brown CM. (2023). Community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. *J Am Pharm Assoc*. 63(5):1558-1565. DOI: 10.1016/j.japh.2023.06.010.
43. **Ostrach B*, **Hill LG**, Carpenter D, Pollini R. (2023). Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. *J Am Pharm Assoc*. 63(4):1044-1048. DOI: 10.1016/j.japh.2023.04.029.
42. **Varisco TJ*, Wanat M, **Hill LG**, Thornton D. (2023). The impact of the Mainstreaming Addiction Treatment Act and associated legislative action on pharmacy practice. *J Am Pharm Assoc*. 63(4):1039-1043. DOI: 10.1016/j.japh.2023.04.016.
41. *Murchison ML*, Loera LJ, ***Hill LG**. (2023). Medications for opioid use disorder in professional recovery programs in the United States: Policies and recommendation patterns. *Ment Health Clin*. 13(3):163-164. DOI: 10.9740/mhc.2023.06.163.
40. **Chatterjee A*, Bannister M, **Hill LG**, Davis CS. (2023). Prescribing syringes to people who inject drugs: Advancing harm reduction in primary care. *J Gen Intern Med*. 38(8):1980-1983. DOI: 10.1007/s11606-023-08183-7.

39. *Claborn KR, Samora J, McCormick K, Whittfield Q, Courtois F, Lozada K, Sledge D, Burwell A, Chavez S, Bailey J, Bailey C, Pederson C, Zagorski C, **Hill LG**, Conway F, Steiker LH, Duncan Cance J, Potter JS. (2023). "We do it ourselves": Strengths and opportunities for improving the practice of harm reduction. *Harm Reduct J.* 20(1):70. DOI: 10.1186/s12954-023-00809-7.
38. Loera LJ, ***Hill LG**, Evoy KE, Reveles KR. (2023). Research and scholarly methods: Audit studies. *J Am Coll Clin Pharm.* 6(5):521-527. DOI: 10.1002/jac5.1782.
37. Britton TR, Clague MR, Zagorski CM, **Hill LG**, *Loera LJ. (2023). A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, Texas. *J Am Pharm Assoc.* 63(1):361-365. DOI: 10.1016/j.japh.2022.10.018.
36. Duncan Cance J, Bingaman A, Kane H, Hairgrove S, *Torrez SB, Buck A, Zagorski CM, Loera LJ, *Hill LG.* (2023). A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas. *J Am Pharm Assoc.* 63(1):317-323. DOI: 10.1016/j.japh.2022.10.005.
35. ***Hill LG**, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. (2023). Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. *J Am Pharm Assoc.* 63(1):252-260. DOI: 10.1016/j.japh.2022.08.017.
34. *Loera LJ, *Hill LG, Zagorski CM, Jermain ML, Tirado CF.* (2023). Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. *Am J Pharm Educ.* 87(1):8926. DOI: 10.5688/ajpe8926.
33. *Lai RK, Friedson KE, Reveles KR, Bhakta K, Gonzales G, Hill LG, *Evoy KE.* (2022). Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review. *J Am Pharm Assoc.* 62(6):1725-1740. DOI: 10.1016/j.japh.2022.07.008.
32. ***Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel H, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR.** (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. *Drug Alcohol Depend.* 237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.
31. *Gugala E, Briggs O, Moczygemba LR, Brown CM, *Hill LG.* (2022). Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice. *Subst Abus.* 43(1):972-987. DOI: 10.1080/08897077.2022.2060423.
30. *White KM, *Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.* (2022). Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. *Subst Abus.* 43(1):749-755. DOI: 10.1080/08897077.2021.2010161.
29. ***Hill LG, Zagorski CM, Loera LJ.** (2022). Increasingly powerful opioid antagonists are not necessary. *Int J Drug Policy.* 99:103457. DOI: 10.1016/j.drugpo.2021.103457.
28. *Evoy KE, **Hill LG, Davis CS.** (2021). Reply to letter to the editor regarding article: "Considering the potential benefits of over-the-counter naloxone". *Integr Pharm Res Pract.* 10:77-78. DOI: 10.2147/IPRP.S327403.
27. ***Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR.** (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. *Addiction.* 116(6):1505-1511. DOI: 10.1111/ADD.15314. **ACCP Ambulatory Care PRN Outstanding Paper of the Year.**
26. *Bottner R, Weems J, **Hill LG, Ziebell C, Long S, Young S, Sasser M, Ferguson A, Tirado C.** (2021). Addiction treatment networks cannot withstand acute crises: Lessons from Winter Storm Uri in Texas. *NAM Perspectives.* DOI: 10.31478/202103c.
25. *Peckham AM, Ball J, Colvard MD, Dadiomov D, **Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.** (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. *Am J Health Syst Pharm.* 78(7):612-618. DOI: 10.1093/ajhp/zxab003. **Innovation in Pharmacy Practice Award – Finalist.**

24. *Evoy KE, **Hill LG**, Davis CS. (2021). Considering the potential benefits of over-the-counter naloxone. *Integr Pharm Res Pract.* 10:13-21. DOI: 10.2147/iprp.S244709.
23. *Coon SA, **Hill LG**, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. (2020). Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy. *J Am Coll Clin Pharm.* 3(8):1493-1513. DOI: 10.1002/jac5.1331.
22. *Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, **Hill LG**, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. (2020). Report of the 2020 special committee on substance use and pharmacy education. *Am J Pharm Educ.* 84(11):8421. DOI: 10.5688/ajpe8421.
21. *Litten K, **Hill LG**, Garza A, Srinivasa M. (2020). Increasing naloxone knowledge and use through direct-to-patient education. *J Pharm Technol.* 36(6):237-242. DOI: 10.1177/8755122520954218.
20. *Renfro ML, Moczygamba LR, Baumgartner J, Baumgart G, **Hill LG**. (2020). Opioid-related education provided by continuing education divisions at US pharmacy schools. *Am J Pharm Educ.* 84(10):8001. DOI: 10.5688/ajpe8001.
19. *Renfro ML, Loera LJ, Tirado CF, **Hill LG**. (2020). Lofexidine for acute opioid withdrawal: A clinical case series. *Ment Health Clin.* 10(5):259-263. DOI: 10.9740/mhc.2020.09.259.
18. *Zagorski CM, Myslinski JM, **Hill LG**. (2020). Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. *Int J Drug Policy.* 86:102939. DOI: 10.1016/j.drugpo.2020.102939.
17. ***Hill LG**, Evoy KE, Reveles KR. (2020). Reply to a letter regarding, "Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction". *J Am Pharm Assoc.* 60(5):e22-23. DOI: 10.1016/j.japh.2020.02.019.
16. *Mackert M, Pounders K, *Brown L*, Kirtz S, Hughes Wagner J, Ring D, **Hill LG**, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Holleran Steiker LK, DeSalvo K, Bernhardt J, Pretorius K. (2020). Development of a health communication campaign to promote the Texas prescription monitoring program. *Health Mark Q.* 37(3):222-231. DOI: 10.1080/07359683.2020.1802967.
15. *Peterson J, Barner J, Lai P, Garza A, Hinds A, Nguyen M, **Hill LG**, Gums T. (2020). Impact of physician-pharmacist covisits at a primary care clinic in patients with uncontrolled diabetes. *J Pharm Pract.* 33(3):321-325. DOI: 10.1177/0897190018807374.
14. ***Hill LG**, Holleran Steiker LK, *Mazin L*, Kinzly ML. (2020). Implementation of a collaborative model for opioid overdose prevention on campus. *J Am Coll Health.* 68(3):223-226. DOI: 10.1080/07448481.2018.1549049.
13. *Evoy KE, *Groff L*, **Hill LG**, *Godinez W*, *Gandhi R*, Reveles KR. (2020). Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. *J Am Pharm Assoc.* 60:81-86. DOI: 10.1016/j.japh.2019.09.007.
12. ***Hill LG**, *Laguado SA*. (2019). Guidance for male mentors to support the safety and success of female mentees. *Am J Pharm Educ.* 83(10):7533. DOI: 10.5688/ajpe7533.
11. ***Hill LG**, Evoy KE, Reveles KR. (2019). Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. *J Am Pharm Assoc.* 59(6):779-782. DOI: 10.1016/j.japh.2019.06.019.
10. ***Hill LG**, Reveles KR, Evoy KE. (2019). State-level approaches to expanding pharmacists' authority to dispense naloxone may affect accessibility. *JAMA Intern Med.* 179(10):1442-1443. DOI: 10.1001/jamainternmed.2019.3653.
9. *Evoy KE, **Hill LG**, *Groff L*, *Mazin L*, *Carlson CC*, Reveles KR. (2018). Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. *JAMA.* 320(18):1934-1937. DOI: 10.1001/jama.2018.15892. **ACCP Ambulatory Care PRN Outstanding Paper of the Year.**

8. ***Hill LG**, Sanchez JP, Laguado SA, Lawson KA. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. *Curr Pharm Teach Learn*. 10(10):1348-1353. DOI: 10.1016/j.cptl.2018.07.010.
7. *Murphy JE, Liles AM, Bingham AL, Chamberlin K, Dang D, **Hill LG**, Lee M, Leonard A, Lodise N, Rogers E. (2018). Interprofessional education: Principles and application. An update from the American College of Clinical Pharmacy. *J Am Coll Clin Pharm*. 1:e17-28. DOI: 10.1002/jac5.1025.
6. *Jordan RP, Bratberg J, Congdon HB, Cross LB, **Hill LG**, Marrs JC, McBane S, Lang WG, Ekoma JO. (2017). The report of the 2016-2017 advocacy standing committee. *Am J Pharm Educ*. 81(8):S10. DOI: 10.5688/ajpeS10.
5. *Han JK, **Hill LG**, Koenig ME, Das N. (2017). Naloxone counseling for harm reduction and patient engagement. *Fam Med*. 49(9):730-733.
4. *Corbo JM, DeLellis TM, **Hill LG**, Rindfuss SL. (2016). ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. *Am Fam Physician*. 94(8):652-653.
3. ***Hill LG**, Chee JS, Haugh AJ, Wilson SA. (2015). Effect of time of day on lipoprotein measurement. *Evidence-Based Practice*. 18(7):11. DOI: 10.1097/01.EBP.0000541014.38985.c7.
2. ***Hill LG**, Dupuis KM. (2015). Compounded vancomycin solution for *Clostridium difficile* infection. *Evidence-Based Practice*. 18(7):2. DOI: 10.1097/01.EBP.0000541002.47570.d0.
1. ***Hill LG**. Lorcaserin and phentermine/topiramate: Two leaps forward in weight loss pharmacotherapy. (2013). *Ann Pharmacother*. 47(12):1740. DOI: 10.1177/1060028013513557.

Peer-Reviewed Conference Abstracts

39. Hendy LE, Lira MC, **Hill LG**, Olguin A, Jimes C, Barrett E, Coffey MJ. (2025). Pharmacy barriers to receiving buprenorphine addiction treatment through telehealth. *J Addict Med*. DOI: 10.1097/ADM.0000000000001572.
38. Zagorski CM, **Hill LG**, Ferguson A, Dasgupta N. (2025). We have the right to know: Building a drug user-owned drug checking network in Texas. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
37. Lines J, Mayberry S, Hilzendager S, **Hill LG**, Sledge DS, Ferguson A, Loera LJ. (2025). Nonprescription syringe and over-the-counter naloxone availability in community pharmacies: A secret shopper purchase audit in Austin, TX. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
36. Garcia SA, Duncan Cance J, Temblador A, Erickson E, Kane H, Loera LJ, **Hill LG**. (2025). A survey of opioid overdose preparedness in Texas school districts. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
35. Rodriguez KA, Loera LJ, Torrez SB, Temblador A, **Hill LG**. (2025). Texas community pharmacists' knowledge, perceptions, and practices related to dispensing buprenorphine for opioid use disorder: A cross-sectional online survey. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
34. Johnson ED, **Hill LG**, Temblador A, Sledge DS, Torrez SB, Loera LJ. (2025). Opioid antagonist knowledge, preferences, and practices among substance use service providers in Texas. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
33. **Hill LG**, Torrez SB, Evoy KE, Reveles KR, Loera LJ. (2025). Increasing buprenorphine and naloxone access in Texas community pharmacies through a mail-based educational intervention. *Subst Use Addctn J*. DOI: 10.1177/29767342251320201.
32. Torrez SB, Loera LJ, Bosworth J, Tran AR, Ukazim GI, **Hill LG**. (2024). Overcoming pharmacy barriers to buprenorphine access through education and communication. *Subst Use Addctn J*. DOI: 10.1177/29767342241228101.

31. *Ukazim GI, Tran AR, Loera LJ, Zagorski CM, Temblador A, Tirado CF, Hill LG.* (2024). Accessibility of office-based buprenorphine treatment for opioid use disorder in Texas. *Subst Use Addctn J.* DOI: 10.1177/29767342241228101.
30. *McCullough H, Kutluk B, Tran AR, Dreymla D, Lumanog E, Nealis L, Kmetz L, Loera LJ, Zagorski CM, Duncan Cance J, Kane H, Hill LG.* (2024). Evaluation of injection drug use and wound care practices of a mobile syringe services program. *Subst Use Addctn J.* DOI: 10.1177/29767342241228101.
29. *Zagorski CM, Ferguson A, Dasgupta N, Hill LG.* (2024). Tars over Texas: A community-driven approach to low-barrier GC-MS drug testing. *Subst Use Addctn J.* DOI: 10.1177/29767342241228101.
28. *Britton T, Clague M, Sobarzo L, Zhang A, Tran S, Moore J, Zagorski CM, Loera LJ, Hill LG.* (2023). A wound care and immunization needs assessment for clients of a mobile syringe services program in Austin, Texas. *Subst Abus.* 44(1):4–11. DOI: 10.1177/08897077231169569.
27. *Johnston KE, Moore JR, Loera LJ, Hill LG.* (2023). Impact of interprofessional substance use disorder education on students' perceptions of addiction and ability to respond to an opioid overdose. *Subst Abus.* 44(1):4–11. DOI: 10.1177/08897077231169569.
26. *Murchison ML, Loera LJ, Hill LG.* (2023). Policies and recommendation frequencies for medications for opioid use disorder in professional recovery programs in the U.S. *Ment Health Clin.* 13(2):74–75. DOI: 10.9740/mhc.2023.04.051.
25. *Puzantian T, Karapetyan N, Saffari MJ, Shaw BA, Singh S, Bokhari F, Reveles KR, Torrez SB, Loera LJ, Hill LG.* (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in California. *Subst Abus.* 43(1):1341–1345. DOI: 10.1080/08897077.2022.2074607.
24. *Torrez SB, Perez JC, White KM, Loera LJ, Reveles KR, Evoy KE, Zagorski C, Bird J, Buck A, Burgess M, Charles A, Gonzalez G, Tran A, Wijeratne A, Yeung M, Ukazim G, Nguyen N, Clague M, Hill LG.* (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Florida. *Subst Abus.* 43(1):1341–1345. DOI: 10.1080/08897077.2022.2074607.
23. *Perez JC, Torrez SB, White KM, Loera LJ, Reveles KR, Evoy KE, Hill LG.* (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in South Dakota. *Subst Abus.* 43(1):1341–1345. DOI: 10.1080/08897077.2022.2074607.
22. *Yeung M, Loera LJ, Peterson MR, Murchison ML, Johnston KE, Prevatt CA, Peterson AM, Reveles KR, Hill LG.* (2022). Buprenorphine/naloxone film and naloxone nasal spray pharmacy deserts in Harris County, Texas and Philadelphia County, Pennsylvania. *Ment Health Clin.* 12(2):98. DOI: 10.9740/mhc.2022.04.089.
21. *Torrez SB, Buck A, Zagorski CM, Loera LJ, Duncan Cance J, Bingaman A, Kane H, Hairgrove S, Hill LG.* (2022). A qualitative report of fentanyl exposure among people who use drugs in Austin, Texas. *Ment Health Clin.* 12(2):94. DOI: 10.9740/mhc.2022.04.089.
20. *Loera LJ, Hill LG, Torrez SB, Puzantian T, Ventricelli DJ, Eukel HN, Evoy KE, Peckham AM, Chen C, Ganetsky VS, Yeung M, Zagorski CM, Reveles KR.* (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in eleven U.S. states. *J Am Coll Clin Pharm.* 4:1631–1755. DOI: 10.1002/jac5.1561.
19. *Loera LJ, Tirado CF, Zagorski CM, Hill LG.* (2021). Description and evaluation of a novel advanced pharmacy practice experience in addiction medicine. *Am J Pharm Educ.* 85(7):8538. DOI: 10.5688/ajpe8738.
18. *Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG.* (2021). Opioid harm reduction: A scoping review of healthcare professional and system-level gaps in knowledge, education, and practice. *J Am Pharm Assoc.* 61:e28-e190. DOI: 10.1016/j.japh.2021.04.021.

17. Vogt CM, Burgess MM, Charles AN, Loera LJ, Tirado CF, Hill LG. (2021). Analysis of patient-reported satisfaction with long-acting injectables for opioid and alcohol use disorder in a Central Texas outpatient clinic. *Ment Health Clin.* 11(2):79-80. DOI: 10.9740/mhc.2021.03.075.
16. Loera LJ, Hill LG, Zagorski CM, Castleberry AN. (2021). Analysis of student pharmacists' intention to provide harm reduction resources after brief education and a simulated patient encounter. *Ment Health Clin.* 11(2):80. DOI: 10.9740/mhc.2021.03.075.
15. White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. (2021). A scoping review of policies regarding use of medications for opioid use disorder in professional recovery programs. *Ment Health Clin.* 11(2):96-97. DOI: 10.9740/mhc.2021.03.075.
14. Hill LG, Torrez SB, Loera LJ, Renfro ML, Reveles KR, Evoy KE. (2021). Assessing the availability of buprenorphine/naloxone in pharmacies via telephone audit: A feasibility pilot. *Subst Abus.* 42(1):1-4. DOI: 10.1080/08897077.2020.1866144.
13. Hill LG, Moore J, Young VS, Erickson C, Velasquez M. (2020). Interprofessional SUD and SBIRT training for health professions students. *J Addict Med.* 14(6):e399. DOI: 10.1097/ADM.0000000000000742.
12. Renfro ML, Loera LJ, Hill LG, Tirado CF. (2020). Lofexidine for acute opioid withdrawal: A clinical case series. *Ment Health Clin.* 10(3):120-121. DOI: 10.9740/mhc.2020.05.104.
11. Loera LJ, Renfro ML, Hill LG, Tirado CF. (2020). Description of a novel advanced pharmacy practice experience in addiction medicine. *Ment Health Clin.* 10(3):191. DOI: 10.9740/mhc.2020.05.104.
10. Janzen K, Mason K, Curran M, Hill LG, Moriates C, Shell K, Smethers K, Bottner R. (2020). The B-Team: Role of the pharmacist in inpatient buprenorphine induction for opioid use disorder. *J Am Coll Clin Pharm.* 3(1):303. DOI: <https://doi.org/10.1002/jac5.1204>.
9. Hill LG, Doan A, Castleberry AN. (2019). Impact of brief education and a simulated patient encounter on student pharmacists' intention to provide harm reduction resources. *Subst Abus.* 40(4):389-391. DOI: 10.1080/08897077.2019.1695039.
8. Renfro ML, Loera LJ, Hill LG, Tirado CF. (2019). Analysis of patient-reported intentional and accidental fentanyl use in a Central Texas treatment facility. *Subst Abus.* 40(4):389-91. DOI: 10.1080/08897077.2019.1695039.
7. Young VS, Seltzer JK, Aguilera L, Hill LG, Acosta WR. (2019). Curricular integration of population health and the IHI model of improvement through interprofessional community engagement. *Am J Pharm Educ.* 83(5):979-80. DOI: 10.5688/ajpe7654.
6. Renfro ML, Moczygamba LR, Baumgartner J, Baumgart G, Hill LG. (2019). U.S. college of pharmacy continuing education departments' role in educating pharmacists about the opioid crisis. *J Am Pharm Assoc.* 59:e207. DOI: 10.1016/j.japh.2019.05.016.
5. Garcia L, Moton R, Lawson KA, Hill LG. (2019). Impact of opioid overdose prevention training and outreach on knowledge and attitudes among first-year pharmacy students. *Ment Health Clin.* 9(3):159-160. DOI: 10.9740/mhc.2019.05.141.
4. Piccuiro SR, Rendon J, Goyal S, Hill LG, Reveles KR, Evoy KE. (2019). Student-led academic detailing regarding naloxone standing orders at chain community pharmacies in Texas. *Ment Health Clin.* 9(3):172. DOI: 10.9740/mhc.2019.05.141.
3. Mazin L, Hill LG, Evoy KE, Lawson KA. (2018). Operation Naloxone: Opioid overdose prevention service learning for health professions students. *Am J Pharm Educ.* 82(5):7158. DOI: 10.5688/ajpe7160.
2. Laguado SA, Sanchez JP, Hill LG. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. *Subst Abus.* 39(1):1. DOI: 10.1080/08897077.2018.1441944.
1. Hill LG. (2015). Naloxone counseling for harm reduction and patient engagement. *Pharmacotherapy.* 35(11): e269-270. DOI: 10.1002/phar.1659.

Book Chapters

5. Hill LG, Loera LJ. (2026). Chapter 89: Substance use disorders I: Opioids, sedatives, stimulants, hallucinogens, and cannabis. In: Haines ST, Nolin TD, Ellingrod VL, Posey LM, Cocohoba J, Holle L. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*. 13th ed. New York, NY: McGraw Hill.
4. Loera LJ, Hill LG. (2026). Chapter e88: Introduction to substance use disorders. In: Haines ST, Nolin TD, Ellingrod VL, Posey LM, Cocohoba J, Holle L. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*. 13th ed. New York, NY: McGraw Hill.
3. Peckham AM, Hill LG. (2021). Harm reduction for people who inject drugs: A life-saving opportunity. In: Covvey JR, Arya V, DiPietro Mager NA, Gilman NV, Herring M, Lukas S, Ochs L, Waddington L, eds. *Public Health in Pharmacy Practice: A Casebook*. 2nd ed. Geneseo, NY: Milne Open Textbooks.
2. Hill LG, Jacobson AN. (2019). Opioid harm reduction. In: Dixon DL, Harris IM, eds. *Ambulatory Care Self-Assessment Program: Neurologic Care and Pain Management*. Lenexa, KS: American College of Clinical Pharmacy.
1. Hill LG. (2018). Harm reduction approaches to opioids. In: Schepis TS, ed. *The Prescription Drug Abuse Epidemic: Incidence, Prevention, Treatment, and Policy*. Santa Barbara, CA: ABC-CLIO, LLC.

Other Publications

12. Varisco TJ, Bolin J, Chi W, Dadiomov D, Essien E, Fish H, Ginsburg D, Hill LG, Scott VG, Song J, Thornton D, Waggener J, Wanat MA, Yazdanfard S. (2023). Developing a consensus practice guideline to address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy. *Open Science Framework*. osf.io/ytmx4.
11. Yeung MS, Johnston KE, Murchison ML, Loera LJ, Hill LG. (2022). Pharmacy: The most accessible healthcare provider, unless you have a substance use disorder. *CPTL Pulses*. <https://bit.ly/4kPKjbm>.
10. Tran T, Hill LG, Alliu V, Pham K. (2022). Issue Brief: Coordinated and comprehensive medication management in substance use disorder treatment and recovery. *Alliance for Addiction Payment Reform*. <https://bit.ly/3LiIB0Q>.
9. Hill LG, Walters S. (2022). The opioid crisis is changing and Texas needs a syringe services program. *The Dallas Morning News*. <https://bit.ly/3BHLt3D>.
8. White KM, Hill LG. (2021). Protocol for a scoping review of medications for opioid use disorder in professional recovery programs. *Open Science Framework*. osf.io/rbvyw/.
7. Hill LG. (2018). Opioid safety and overdose prevention. *iForumRx*. <https://bit.ly/32Zkz7a>.
6. Shin J, Hill LG. (2017). Painstaking efforts to improve opioid stewardship. *iForumRx*. <https://bit.ly/2TUGkzO>.
5. Hill LG. (2017). The opioid epidemic: Texas prevention strategies. *Texas Pharmacy*. Summer;6-7.
4. Hill LG. (2016). Coprescribing naloxone: A moral imperative. *iForumRx*. <https://bit.ly/3oSUFly>.
3. Mootz ML, Hill LG. (2016). PATHWAY-2 right treatment. *iForumRx*. <https://bit.ly/3IMkL0F>.
2. Trietley GS, Hill LG. (2015). SGLT2 and you: A novel target for diabetes treatment. *Bulletin of the Allegheny County Medical Society*. April;169-171.
1. Hill LG, Castelli GB. (2014). Cannabis considered. *Bulletin of the Allegheny County Medical Society*. November;452-454.

Peer-Reviewed National Presentations

Platforms

26. Lira M, Johnson J, **Hill LG**, Hendy L, Hom J. Addressing low buprenorphine stocking as a barrier to opioid use disorder treatment. College on Problems of Drug Dependence Annual Scientific Meeting; Portland, OR; June 2026.
25. *Zagorski CM*, **Hill LG**, Ferguson A, Dasgupta N. We have the right to know: Building a drug user-owned drug checking network in Texas. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
24. *Lines J*, *Mayberry S*, *Hilzendager S*, **Hill LG**, Sledge DS, Ferguson A, Loera LJ. Nonprescription syringe and over-the-counter naloxone availability in community pharmacies: A secret shopper purchase audit in Austin, TX. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
23. *Torrez SB*, Loera LJ, Bosworth J, *Tran AR*, *Ukazim GI*, **Hill LG**. Overcoming pharmacy barriers to buprenorphine access through education and communication. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Washington, D.C.; November 2023.
22. Varisco TJ, Thornton DJ, **Hill LG**. Geospatial and social determinants of access to buprenorphine providers and pharmacies. Rx and Illicit Drug Summit; April 2023.
21. *Zagorski CM*, Loera LJ, Vargas-Estrella B, **Hill LG**. Naloxone, nalmefene and unintended consequences: A closer look at the opioid antagonist arms race. National Harm Reduction Conference; San Juan, PR; October 2022.
20. Luk J, Young V, Timmerman GM, Jones B, **Hill LG**, Sparks D, Hinojosa-Galvan S. Establishing a foundation for interprofessional collaborative practice through a longitudinal course for pre-clinical learners. Nexus Summit; October 2021.
19. Ventricelli DJ, **Hill LG**, Odem S, Johnson H, Werremeyer A. No waiver required: What pharmacists need to know about buprenorphine for opioid use disorder treatment. American Association of Colleges of Pharmacy Annual Meeting; July 2021.
18. *Gugala E*, *Briggs O*, *Moczygemba LR*, Brown CM, **Hill LG**. Opioid harm reduction: A scoping review of healthcare professional and system-level gaps in knowledge, education, and practice. American Pharmacists Association Annual Meeting & Exposition; March 2021.
17. **Hill LG**, Palombi L, Peckham AM, Wilson CG, Ramage M. Developing the future addiction treatment workforce through experiential education. American Association of Colleges of Pharmacy Annual Meeting; Long Beach, CA; July 2020.
16. **Hill LG**, *Doan A*, Castleberry AN. Impact of brief education and a simulated patient encounter on student pharmacists' intention to provide harm reduction resources. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2019.
15. Tran T, **Hill LG**, Hager K, Muzyk A, Baugh G. Successful attributes of interprofessional education in substance use disorder. American Association of Colleges of Pharmacy Annual Meeting; Chicago, IL; July 2019.
14. Brown LE, Mackert M, Pounders K, Kirtz S, Ring D, Wagner JH, **Hill LG**, Rakasovic D. Difficult patient-provider conversations: Prescription opioids and safe and effective alleviation of pain. International Communication Association Annual Meeting; Washington, D.C.; May 2019.
13. Mackert M, Pounders K, Kirtz S, Wagner JH, Brown L, Lewellyn K, Ring D, Wilcox G, Murthy D, **Hill LG**, Innerarity S, Tierney W, McGlone M, Holleran Steiker LK, Bernhardt J, DeSalvo K. Developing a statewide campaign to promote use of the Texas prescription monitoring program. U.S. Centers for Disease Control & Prevention National Conference on Health Communication, Marketing, and Media; Atlanta, GA; September 2018.

12. Bratberg JP, **Hill LG**, Tran TA, Ventricelli DJ, Wheeler M, Ochs L. Evidence-based solutions for people who use opioids to reduce mortality and morbidity. American Association of Colleges of Pharmacy Annual Meeting; Boston, MA; July 2018.
11. Holleran Steiker LK, **Hill LG**. Bringing opioid awareness and overdose prevention to a college campus. National Association of Alcoholism and Drug Addiction Counselors Annual Meeting; Denver, CO; September 2017.
10. Bratberg JP, **Hill LG**, Freeman PR, Palmer E, Melton ST, Kwon M, Moody A, Covvey JR. Integrating opioid safety and overdose prevention across the curriculum. American Association of Colleges of Pharmacy Annual Meeting; Nashville, TN; July 2017.
9. Young VS, **Hill LG**. Rapid-cycle improvement for agile curricular transformation in interprofessional education. American Association of Colleges of Pharmacy Annual Meeting; Nashville, TN; July 2017.
8. **Hill LG**, Holleran Steiker LK, Castedo SJ, Barnes JN. Implementing the ACHA opioid guideline to promote rational prescribing, overdose prevention, and recovery support on campus. American College Health Association Annual Meeting; Austin, TX; June 2017.
7. **Hill LG**, Koenig ME. Naloxone counseling for harm reduction and patient engagement. Society of Teachers of Family Medicine Conference on Practice Improvement; Dallas, TX; December 2015.
6. **Hill LG**, Higbea AM. iPharm: Demolishing silos in the patient-centered medical home. Society of Teachers of Family Medicine Conference on Practice Improvement; Dallas, TX; December 2015.
5. Das N, **Hill LG**. Pill burden: Targeting polypharmacy using a home visit model. Society of Teachers of Family Medicine Conference on Practice Improvement; Dallas, TX; December 2015.
4. **Hill LG**, Sphar BE. Cannabis as medicine: Practical considerations. Society of Teachers of Family Medicine Annual Spring Conference; Orlando, FL; April 2015.
3. **Hill LG**, Hendry SE. Demystifying trial analysis in the age of evidence-based medicine. Society of Teachers of Family Medicine Annual Spring Conference; Orlando, FL; April 2015.
2. Sairenji T, **Hill LG**. Building a home visit curriculum in a family medicine residency. Society of Teachers of Family Medicine Annual Spring Conference; Orlando, FL; April 2015.
1. **Hill LG**, Hendry SE. Strategies for integrating pharmacy trainees into family medicine teams. Society of Teachers of Family Medicine Annual Spring Conference; San Antonio, TX; May 2014.

Posters

57. Varisco TJ, Thornton D, Hussain T, Fish H, Bolin J, Dadiomov D, Essien EJ, Wanat MA, Ginsburg D, Waggener J, Bratberg J, DiPaula B, **Hill LG**. Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-ODU Expert Panel. College on Problems of Drug Dependence Annual Scientific Meeting; New Orleans, LA; June 2025.
56. Varisco TJ, Fish H, Bolin J, **Hill LG**, Dadiomov D, Essien EJ, Wanat MA, Ginsburg D, Waggner J, Hussain T, Bratberg JP, Thornton D. The Pharmacy Access to Resources and Medication for Opioid Use Disorder Practice Guideline: Consensus recommendations for pharmacists and distributors. National Academy of Medicine Innovations in Pharmacy Training and Practice To Advance Patient Care; Washington, DC; May 2025.
55. Hedy LE, Lira MC, **Hill LG**, Olguin A, James C, Barrett E, Coffey MJ. Pharmacy barriers to receiving buprenorphine addiction treatment through telehealth. American Society of Addiction Medicine Annual Meeting; Denver, CO; April 2025.

54. *Garcia SA, Duncan Cance J, Temblador A, Erickson E, Kane H, Loera LJ, Hill LG.* A survey of opioid overdose preparedness in Texas school districts. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
53. *Rodriguez KA, Loera LJ, Torrez SB, Temblador A, Hill LG.* Texas community pharmacists' knowledge, perceptions, and practices related to dispensing buprenorphine for opioid use disorder: A cross-sectional online survey. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
52. *Johnson ED, Hill LG, Temblador A, Sledge DS, Torrez SB, Loera LJ.* Opioid antagonist knowledge, preferences, and practices among substance use service providers in Texas. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
51. *Hill LG, Torrez SB, Evoy KE, Reveles KR, Loera LJ.* Increasing buprenorphine and naloxone access in Texas community pharmacies through a mail-based educational intervention. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Chicago, IL; November 2024.
50. *Zalmai R, Baffoe J, Hill LG, Loera LJ, Johnsrud M, Avanceña A.* Predictors of buprenorphine treatment retention among privately insured adults with opioid use disorder. Academy of Managed Care Pharmacy Nexus; Las Vegas, NV; October 2024.
49. *Varisco T, Torrez SB, Loera LJ, Thornton DJ, Hill LG.* Using interpretable machine learning to predict access to buprenorphine in pharmacies. American Society of Addiction Medicine Annual Meeting; Dallas, TX; April 2024.
48. *Ukazim GI, Tran AR, Loera LJ, Zagorski CM, Temblador A, Tirado CF, Hill LG.* Accessibility of office-based buprenorphine treatment for opioid use disorder in Texas. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Washington, D.C.; November 2023.
47. *McCullough H, Kutluk B, Tran AR, Dreymla D, Lumanog E, Nealis L, Kmetz L, Loera LJ, Zagorski CM, Duncan Cance J, Kane H, Hill LG.* Evaluation of injection drug use and wound care practices of a mobile syringe services program. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Washington, D.C.; November 2023.
46. *Zagorski CM, Ferguson A, Dasgupta N, Hill LG.* Tars over Texas: A community-driven approach to low-barrier GC-MS drug testing. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Washington, D.C.; November 2023.
45. *Murchison ML, Loera LJ, Hill LG.* Policies and recommendation frequencies for medications for opioid use disorder in professional recovery programs in the U.S. American Association of Psychiatric Pharmacists; April 2023.
44. *Britton T, Clague M, Sobarzo L, Zhang A, Tran S, Moore J, Zagorski CM, Loera LJ, Hill LG.* A wound care and immunization needs assessment for clients of a mobile syringe services program in Austin, Texas. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2022.
43. *Johnston KE, Moore JR, Loera LJ, Hill LG.* Impact of interprofessional substance use disorder education on students' perceptions of addiction and ability to respond to an opioid overdose. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2022.
42. *Torrez SB, Buck A, Zagorski CM, Loera LJ, Duncan Cance J, Bingaman A, Kane H, Hairgrove S, Hill LG.* A qualitative report of fentanyl exposure among people who use drugs in Austin, Texas. National Harm Reduction Conference; San Juan, PR; October 2022.

41. *Yeung M, Loera LJ, Peterson MR, Murchison ML, Johnston KE, Prevatt CA, Peterson AM, Reveles KR, Hill LG.* Buprenorphine/naloxone film and naloxone nasal spray pharmacy deserts in Harris County, Texas and Philadelphia County, Pennsylvania. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2022.
 40. *Torrez SB, Buck A, Zagorski CM, Loera LJ, Duncan Cance J, Bingaman A, Kane H, Hairgrove S, Hill LG.* A qualitative report of fentanyl exposure among people who use drugs in Austin, Texas. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2022.
 39. *Buck A, Bird J, Tirado CF, Loera LJ, Hill LG.* Analysis of clinical characteristics of Travis County patients in a Central Texas outpatient substance use clinic. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2021.
 38. *Houser E, Bicker AM, Torrez SB, Loera LJ, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Arizona. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2021.
 37. *Pac W, Haley A, Nieman M, Notarianni V, Son D, Roy S, Ventricelli DJ, Torrez SB, Loera LJ, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Pennsylvania. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2021.
 36. *Puzantian T, Karapetyan N, Safari MJ, Shaw BA, Singh S, Bokhari F, Reveles KR, Torrez SB, Loera LJ, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in California. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; November 2021.
 35. *Torrez SB, Perez JC, White KM, Loera LJ, Reveles KR, Evoy KE, Zagorski C, Bird J, Buck A, Burgess M, Charles A, Gonzalez G, Tran A, Wijeratne A, Yeung M, Ukazim G, Nguyen N, Clague M, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Florida. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; November 2021.
 34. *Perez JC, Torrez SB, White KM, Loera LJ, Reveles KR, Evoy KE, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in South Dakota. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; November 2021.
 33. *Loera LJ, Hill LG, Torrez SB, Puzantian T, Ventricelli DJ, Eukel HN, Evoy KE, Peckham AM, Chen C, Ganetsky VS, Yeung M, Zagorski CM, Reveles KR.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in eleven U.S. states. American College of Clinical Pharmacy Annual Meeting; October 2021.
- Research Fellowship Best Poster.**
32. *Loera LJ, Tirado CF, Zagorski CM, Hill LG.* Description and evaluation of a novel advanced pharmacy practice experience in addiction medicine. American Association of Colleges of Pharmacy Annual Meeting; July 2021. **Best Poster by a Resident, Fellow, or Postdoc – Finalist.**
 31. *Vogt CM, Burgess MM, Charles AN, Loera LJ, Tirado CF, Hill LG.* Analysis of patient-reported satisfaction with long-acting injectables for opioid and alcohol use disorder in a Central Texas outpatient clinic. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2021.
 30. *Loera LJ, Hill LG, Zagorski CM, Castleberry AN.* Analysis of student pharmacists' intention to provide harm reduction resources after brief education and a simulated patient encounter. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2021.
 29. *White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.* A scoping review of policies regarding use of medications for opioid use disorder in professional recovery programs. College of Psychiatric & Neurologic Pharmacists Annual Meeting; April 2021.

28. *Nicholson MA, Patel RY, Solis JA, Evoy KE, Reveles KR, Torrez SB, Loera LJ, Hill LG.* Maintaining momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Ohio. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2020.
27. *Burgess MM, Charles A, Vogt C, Reveles KR, Evoy KE, Torrez SB, Loera LJ, Hill LG.* Maintaining momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Massachusetts. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2020.
26. *Charles A, Burgess MM, Vogt C, Reveles KR, Evoy KE, Torrez SB, Loera LJ, Hill LG.* Maintaining momentum on the road to recovery: availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Maine. American Society of Health-System Pharmacists Midyear Clinical Meeting; December 2020.
25. *Hill LG, Torrez SB, Loera LJ, Renfro ML, Reveles KR, Evoy KE.* Assessing the availability of buprenorphine/naloxone in pharmacies via telephone audit: A feasibility pilot. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2020.
24. *Hill LG, Moore J, Young VS, Erickson C, Velasquez M.* Interprofessional SUD and SBIRT training for health professions students. American Society of Addiction Medicine Annual Conference; Denver, CO; April 2020.
23. *Loera LJ, Renfro ML, Tirado CF, Hill LG.* Description of a novel advanced pharmacy practice experience in addiction medicine. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Dallas, TX; March 2020.
22. *Renfro ML, Loera LJ, Tirado CF, Hill LG.* Lofexidine for acute opioid withdrawal: A clinical case series. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Dallas, TX; March 2020.
21. *Loera LJ, Renfro ML, Hill LG, Winiacki A, Tirado CF.* Analysis of patient-reported intentional and accidental fentanyl use in a Central Texas treatment facility. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; Boston, MA; November 2019.
20. *Janzen KM, Mason KR, Curran MF, Hill LG, Moriates C, Smethers K, Bottner R.* The B-Team: Role of the pharmacist in inpatient buprenorphine induction for opioid use disorder. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; New York, NY; October 2019.
19. *Young VS, Seltzer J, Aguilera L, Hill LG, Acosta WR.* Curricular integration of population health and the IHI model of improvement through interprofessional community engagement. American Association of Colleges of Pharmacy Annual Meeting; Chicago, IL; July 2019.
18. *Garcia L, Moton R, Lawson KA, Hill LG.* Impact of opioid overdose prevention training and outreach on knowledge and attitudes among first-year pharmacy students. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Salt Lake City, UT; March 2019.
17. *Piccuirro SR, Rendon J, Goyal S, Hill LG, Reveles KR, Evoy KE.* Student-led academic detailing regarding naloxone standing orders at chain community pharmacies in Texas. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Salt Lake City, UT; March 2019.
16. *Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG.* U.S. college of pharmacy continuing education departments' role in educating pharmacists about the opioid crisis. American Pharmacists Association Annual Meeting & Exposition; Seattle, WA; March 2019.
15. *Litten K, Garza A, Srinivasa M, Falcon P, Hill LG.* Increasing naloxone knowledge and use through direct-to-consumer education. American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 2018.

14. *Piccuiri SR, Rendon J, Hill LG, Reveles KR, Evoy KE.* Student-led academic detailing regarding naloxone standing orders at chain community pharmacies in Texas. American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 2018.
13. *Carlson CC, Mazin L, Groff L, Hill LG, Reveles KR, Evoy KE.* A statewide assessment of naloxone availability at community pharmacies with naloxone standing orders in Texas. American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 2018.
12. *Patterson J, Rubio A, Hill LG, Reveles KR, Evoy KE.* An exploratory analysis of the correlation between opioid overdose mortality rates and naloxone access via standing order in Texas. American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 2018.
11. *Rawson D, Rodriguez A, Allen S, Hill LG, Evoy KE.* Operation Naloxone: Medical student-led opioid overdose prevention training. American Academy of Addiction Psychiatry Annual Meeting; Bonita Springs, FL; December 2018.
10. *Mazin L, Carlson CC, Groff L, Hill LG, Reveles KR, Evoy KE.* Statewide assessment of naloxone accessibility under standing order from community pharmacies in Texas. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 2018.
9. *Mazin L, Hill LG, Evoy KE, Lawson KA.* Operation Naloxone: Multi-institutional opioid overdose prevention service learning for health professions students. American Association of Colleges of Pharmacy Annual Meeting; Boston, MA; July 2018.
8. *Labay C, Garcia L, Mazin L, Hill LG.* Promoting opioid overdose prevention on campus. Association of Recovery in Higher Education National Conference; Houston, TX; July 2018.
7. *Laguado SA, Sanchez JP, Hill LG.* Operation Naloxone: Overdose prevention service learning for student pharmacists. Association for Medical Education and Research in Substance Abuse Annual National Conference; Washington, DC; October 2017.
6. *Sanchez JP, Laguado SA, Hill LG.* Operation Naloxone: Overdose prevention service learning for student pharmacists. American College of Clinical Pharmacy Virtual Poster Symposium; May 2017.
5. *Laguado SA, Sanchez JP, Hill LG.* Operation Naloxone: Overdose prevention service learning for student pharmacists. College of Psychiatric and Neurologic Pharmacists Annual Meeting; Phoenix, AZ; April 2017. **Research Trainee Award – Finalist.**
4. **Hill LG, Han JK.** Naloxone counseling for harm reduction and patient engagement. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; San Francisco, CA; October 2015.
3. **Hill LG, Higbea AM.** iPharm: Demolishing silos in the patient-centered medical home. Society of Teachers of Family Medicine Annual Spring Conference; Orlando, FL; April 2015.
2. **Trietley GS, Hill LG.** A curriculum on purple pills, butterflies, and bathtubs. Society of Teachers of Family Medicine Annual Spring Conference; Orlando, FL; April 2015.
1. **Hill LG, Koenig ME.** Impact of integrated behavioral health program on diabetes management. Society of Teachers of Family Medicine Annual Spring Conference; San Antonio, TX; May 2014.

Peer-Reviewed Regional Presentations

Platforms

14. *Rodriguez KA, Robinson DM, Loera LJ, Torrez SB, Temblador A, Hill LG.* Texas community pharmacist perspectives and knowledge on buprenorphine dispensing for opioid use disorder: A cross-sectional online survey. UT College of Pharmacy Research Day; April 2025. **Best PharmD Student Abstract Award.**

13. *Loera LJ, Hill LG, Zagorski CM, Castleberry AN.* Analysis of student pharmacists' intention to provide harm reduction resources after brief education and a simulated patient encounter. UT College of Pharmacy Research Day; April 2021. **Best Postdoctoral Fellow Abstract Award.**
12. *Evoy KE, Hill LG.* Recent research in community pharmacy access to buprenorphine/naloxone and naloxone for opioid use disorder pharmacotherapy. Texas Society of Health System Pharmacists Annual Seminar; April 2021.
11. *Luk JC, Young VS, Timmerman GM, Jones BL, Hill LG, Sparks D.* An interprofessional socialization pedagogy: Preparing students to enter the clinical learning environment. UT Shine Academy Innovations in Health Science Education Annual Conference; Austin, TX; February 2021.
10. *Tran M, Godinez W, Gandhi R, Contreras J, Alfaro I, Giang D, Chan J, Hill LG, Reveles KR, Evoy KE.* Naloxone accessibility under standing orders from Texas community pharmacies and the efficacy of brief academic detailing on improving accessibility. UT College of Pharmacy Research Day; Austin, TX; April 2019. **Best PharmD Program Abstract Award.**
9. *Litten K, Hill LG, Garza A, Srinivasa M, Falcon P.* Increasing naloxone knowledge and use through direct-to-consumer education. Alcalde Southwest Leadership Conference; Frisco, TX; April 2019.
8. **Hill LG, Ramirez L, Kinzly ML.** Innovative opioid overdose prevention. Healthier Texas Summit; Austin, TX; October 2018.
7. **Hill LG, Barnes JN, Laguado SA, Sanchez JP.** Operation Naloxone: Overdose prevention service learning for student pharmacists. Texas Society of Health-System Pharmacists Annual Seminar; Galveston, TX; April 2017.
6. **Hill LG, Laguado SA, Sanchez JP.** Operation Naloxone: Overdose prevention service learning for student pharmacists. UT McCombs School of Business: Leading Ethical Improvement in Healthcare; Austin, TX; April 2017.
5. *Holleran Steiker LK, Hill LG, Barnes JN.* Operation Naloxone: Overdose prevention on campus. UT McCombs School of Business: Leading Ethical Improvement in Healthcare; Austin, TX; April 2017.
4. **Hill LG.** Naloxone counseling for harm reduction and patient engagement. UT McCombs School of Business: Innovations in Healthcare Delivery Symposium; Austin, TX; April 2016.
3. **Hill LG, Han JK.** iPharm: Demolishing silos in the patient-centered medical home. Family Medicine Education Consortium Northeast Regional Meeting; Alexandria, VA; October 2014.
2. *Han JK, Hill LG.* Utilization of a naloxone counseling letter to improve opioid prescribing. Family Medicine Education Consortium Northeast Regional Meeting; Alexandria, VA; October 2014.
1. *Han JK, Greenlee AR, Hill LG.* Effective, sustainable behavioral health integration. Family Medicine Education Consortium Northeast Regional Meeting; Alexandria, VA; October 2014.

Posters

60. *Lines J, Mayberry S, Hilzendager S, Hill LG, Sledge DS, Ferguson A, Loera LJ.* Nonprescription syringe and over-the-counter naloxone availability in community pharmacies: A secret shopper purchase audit in Austin, TX. UT College of Pharmacy Research Day; April 2025.
59. *Johnson ED, Hill LG, Temblador A, Sledge DS, Torrez SB, Loera LJ.* Opioid antagonist knowledge, preferences, and practices among substance use service providers in Texas. UT College of Pharmacy Research Day; April 2025.
58. *Zagorski CM, Ferguson A, Dasgupta N, Hill LG.* Tars over Texas: A community-driven approach to low-barrier GC-MS drug testing. UT College of Pharmacy Research Day; April 2025.

57. *Zalmai R, Baffoe J, Hill LG, Loera LJ, Johnsrud M, Avanceña A.* Predictors of buprenorphine treatment retention among privately insured adults with opioid use disorder. Southern Pharmacy Administration Conference; Athens, GA; August 2024.
56. *Torrez SB, Evoy KE, Reveles KR, Loera LJ, Hill LG.* Increasing buprenorphine access in Texas community pharmacies through an academic detailing intervention. UT College of Pharmacy Research Day; April 2024.
55. *Ukazim GI, Tran AR, Loera LJ, Zagorski CM, Temblador A, Tirado CF, Hill LG.* Accessibility of office-based buprenorphine treatment for opioid use disorder in Texas. UT College of Pharmacy Research Day; April 2024.
54. *McCullough H, Kutluk B, Tran AR, Dreymla D, Lumanog E, Nealis L, Kmetz L, Loera LJ, Zagorski CM, Duncan Cance J, Kane H, Hill LG.* Evaluation of injection drug use and wound care practices of a mobile syringe services program. UT College of Pharmacy Research Day; April 2024.
53. *Hilzendager S, Lines J, Mayberry S, Hill LG, Sledge D, Ferguson A, Loera LJ.* Nonprescription syringe and over-the-counter naloxone availability in community pharmacies: A secret shopper purchase audit in Austin, TX. UT Center for Health Interprofessional Practice & Education Showcase; April 2024.
52. *Garcia SA, Loera LJ, Temblador A, Lower K, Inglis AJ, Bobker H, Zagorski CM, Hill LG.* Exploring opportunities to expand naloxone access and save lives on campus: A SHIFTovation project report. UT Center for Health Interprofessional Practice & Education Showcase; April 2024. **Best in Quality Improvement – Finalist.**
51. *Ukazim GI, Tran AR, Loera LJ, Zagorski CM, Temblador A, Tirado CF, Hill LG.* Accessibility of office-based buprenorphine treatment for opioid use disorder in Texas. Texas Substance Use Symposium; February 2024.
50. *Zagorski CM, Ferguson A, Dasgupta N, Hill LG.* Tars over Texas: A community-driven approach to low-barrier GC-MS drug testing. Texas Substance Use Symposium; February 2024.
49. *Henretty K, Gibbons B, Williams J, Hill LG, Duncan Cance J.* Characteristics of drug use related infection hospitalizations and emergency department visits in Texas. Texas Substance Use Symposium; February 2024.
48. *Kutluk B, McCullough H, Tran A, Dreymla D, Lumanog E, Nealis L, Kmetz L, Loera LJ, Zagorski CM, Hill LG.* Assessing wound care knowledge and practices among people who inject drugs who participate in a mobile syringe services program in Austin, Texas. UT Center for Health Interprofessional Practice & Education Showcase; April 2023. **Best Visual Poster Award.**
47. *Zalmai R, Hill LG, Loera LJ, Mosgrove Q, Brown CM.* Community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. UT College of Pharmacy Research Day; April 2023.
46. *Duncan Cance J, Hairgrove S, Kane H, Hill LG.* Trends in pharmacy dispensed naloxone in Texas, 2016-2021. Texas Substance Use Symposium; March 2023.
45. *Hairgrove S, Duncan Cance J, Kane H, Hill LG.* Assessing the impact of opioid use disorder online continuing education on the knowledge, attitudes, and beliefs of clinicians. Texas Substance Use Symposium; March 2023.
44. *Zalmai R, Hill LG, Loera LJ, Mosgrove Q, Brown CM.* Community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. Texas Substance Use Symposium; March 2023.
43. *Cowley C, Yan D, Holan C, Johnston K, Moore J, Hill LG.* Changing the Tide: Is Interprofessional Education the Best Place for Substance Use Disorder Education? UT Center for Health Interprofessional Practice & Education Showcase; April 2022.

42. Britton T, Clague M, Sobarzo L, Zhang A, Tran S, Moore J, Zagorski CM, Loera LJ, Hill LG. A wound care and immunization needs assessment for clients of a mobile syringe services program. UT Center for Health Interprofessional Practice & Education Showcase; April 2022.
41. Yeung M, Loera LJ, Peterson MR, Murchison ML, Johnston KE, Prevatt CA, Peterson AM, Reveles KR, Hill LG. Buprenorphine/naloxone film and naloxone nasal spray pharmacy deserts in Harris County, Texas and Philadelphia County, Pennsylvania. UT College of Pharmacy Research Day; April 2022.
40. Torrez SB, Buck A, Zagorski CM, Loera LJ, Duncan Cance J, Bingaman A, Kane H, Hairgrove S, Hill LG. A qualitative report of fentanyl exposure among people who use drugs in Austin, Texas. UT College of Pharmacy Research Day; April 2022.
39. Loera LJ, Hill LG, Torrez SB, Puzantian T, Ventricelli DJ, Eukel HN, Evoy KE, Peckham AM, Chen C, Ganetsky VS, Yeung M, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in eleven U.S. states. UT College of Pharmacy Research Day; April 2022.
38. Loera LJ, Hill LG, Torrez SB, Puzantian T, Ventricelli DJ, Eukel HN, Evoy KE, Peckham AM, Chen C, Ganetsky VS, Yeung M, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in eleven U.S. states. Texas Substance Use Symposium; March 2022.
37. Puzantian T, Shaw BA, Singh S, Bokhari F, Safari MJ, Karapetyan N, Reveles KR, Torrez SB, Loera LJ, Hill LG. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in California. California Society of Health-System Pharmacists Annual Seminar; November 2021.
36. Chen C, Ganetsky VS, Heil J, Loera LJ, Hill LG. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in New Jersey. New Jersey Pharmacists Association Annual Convention; October 2021.
35. Khan R, Hill LG. Naloxone training directed toward high school students to increase awareness of opioid overdoses. JPS Health Network Research & Quality Symposium; Fort Worth, TX; June 2021.
34. Lawson KA, Baumgart G, Richards K, Bosworth J, Moczygemba L, Johnsrud M, Barner J, Hill LG. Impact of brief online continuing education on health professionals' knowledge and attitudes related to opioid use disorder. Texas Substance Use Symposium; April 2021.
33. Loera LJ, Hill LG, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Texas Substance Use Symposium; April 2021.
32. White KM, Vargus A, Levine A, Buck A, Are O, Khan H, Zagorski CM, Hill LG. The impact of COVID-19 on access to harm reduction services among people who use drugs in Austin, TX. Texas Substance Use Symposium; April 2021.
31. Zagorski CM, Baumgart G, Hill LG. Pedagogical approaches to optimizing opioid-related outcomes: The Texas Opioid Training Initiative. Texas Substance Use Symposium; April 2021.
30. Vargus A, White KM, Levine A, Buck A, Are O, Khan H, Zagorski CM, Hill LG. The impact of COVID-19 on access to harm reduction services among people who use drugs in Austin, TX. UT Center for Health Interprofessional Practice & Education Showcase; April 2021.
29. Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG. Opioid harm reduction: A scoping review of healthcare professionals system-level gaps in knowledge, education, and practice. UT College of Pharmacy Research Day; April 2021.
28. Perez JC, Torrez SB, White KM, Loera LJ, Reveles KR, Evoy KE, Hill LG. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in South Dakota. UT College of Pharmacy Research Day; April 2021.

27. *Torrez SB, Perez JC, White KM, Loera LJ, Reveles KR, Evoy KE, Zagorski C, Bird J, Buck A, Burgess M, Charles A, Gonzalez G, Tran A, Wijeratne A, Yeung M, Ukazim G, Nguyen N, Clague M, Hill LG.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Florida. UT College of Pharmacy Research Day; April 2021.
26. *Zagorski CM, Myslinski JM, Hill LG.* Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. UT College of Pharmacy Research Day; April 2021.
25. *Loera LJ, Hill LG, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR.* Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. UT College of Pharmacy Research Day; April 2021.
24. *White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.* A scoping review of policies regarding use of medications for opioid use disorder in professional recovery programs. UT College of Pharmacy Research Day; April 2021.
23. *Nicholson MA, Patel RY, Solis JA, Evoy KE, Reveles KR, Torrez SB, Loera LJ, Hill LG.* Maintaining momentum on the road to recovery: Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Ohio. UT College of Pharmacy Research Day; April 2021.
22. *Burgess MM, Charles A, Vogt C, Reveles KR, Evoy KE, Torrez SB, Loera LJ, Hill LG.* Maintaining momentum on the road to recovery: Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Massachusetts. UT College of Pharmacy Research Day; April 2021.
21. *Vogt CM, Burgess MM, Charles AN, Loera LJ, Tirado CF, Hill LG.* Analysis of patient-reported satisfaction with long-acting injectables for opioid and alcohol use disorder in a Central Texas outpatient clinic. UT College of Pharmacy Research Day; April 2021.
20. *Vogt C, James RI, Dy CK, Jones M, Villareal S, Hill LG.* A survey of people who inject drugs in the Austin community to determine the preferred method of reporting naloxone use. UT Center for Health Interprofessional Practice & Education Showcase; May 2020.
19. *Litten K, Hill LG, Garza A, Srinivasa M, Falcon P.* Increasing naloxone knowledge and use through direct-to-consumer education. CommUnityCare Research and Quality Improvement Meeting; Austin, TX; March 2020.
18. *Dubakula VV, Burgess MM, Castleberry AN, Hill LG.* Impact of brief opioid overdose prevention training for laypersons. Dell Med Educational Innovation, Research, & Awards Symposium; Austin, TX; September 2019.
17. *Addison JD, Loera LJ, Maskov YN, Quintanilla J, Wolf A, Yabar P, Colbert AK, Hill LG.* What are campuses doing to address prescription drug misuse among students? UT Center for Health Interprofessional Practice & Education Showcase; Austin, TX; May 2019.
16. *Garcia L, Keerikattu L, Leal T, Premji N, Senthil S, Curry K, Hill LG.* NAMI in the Lobby: Promoting mental health resources in an Austin area psychiatric hospital. UT Center for Health Interprofessional Practice & Education Showcase; Austin, TX; May 2019.
15. *Moton R, Garcia L, Lawson KA, Hill LG.* Impact of opioid overdose prevention training and outreach on knowledge and attitudes among first-year pharmacy students. UT College of Pharmacy Research Day; Austin, TX; April 2019. **Best PharmD Program Poster Award.**
14. *Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG.* U.S. college of pharmacy continuing education departments' role in educating pharmacists about the opioid crisis. UT College of Pharmacy Research Day; Austin, TX; April 2019.
13. *Litten K, Hill LG, Garza A, Srinivasa M, Falcon P.* Increasing naloxone knowledge and use through direct-to-consumer education. UT College of Pharmacy Research Day; Austin, TX; April 2019.

12. *Tran M, Godinez W, Gandhi R, Contreras J, Alfaro I, Giang D, Chan J, Hill LG, Reveles KR, Evoy KE.* Naloxone accessibility under standing orders from Texas community pharmacies and the efficacy of brief academic detailing on improving accessibility. UT College of Pharmacy Research Day; Austin, TX; April 2019.
11. *Godinez W, Gandhi R, Contreras J, Alfaro I, Giang D, Tran M, Chan J, Hill LG, Reveles KR, Evoy KE.* Naloxone accessibility under standing orders from Texas community pharmacies and the efficacy of brief academic detailing on improving accessibility. Texas Society of Health-System Pharmacists Annual Seminar; Frisco, TX; April 2019.
10. *Rawson D, Rodriguez A, Hill LG, Evoy KE.* Operation Naloxone: Medical student-led opioid overdose prevention training. UT Health San Antonio Cultural Inclusion Institute Conference; San Antonio, TX; April 2019.
9. *Rawson D, Rodriguez A, Allen S, Hill LG, Evoy KE.* Operation Naloxone: Interprofessional overdose prevention service learning. UT Health San Antonio Center for Service Learning Annual Conference; San Antonio, TX; February 2019.
8. *Godinez W, Gandhi R, Contreras J, Alfaro I, Giang D, Tran M, Chan J, Hill LG, Reveles KR, Evoy KE.* Naloxone accessibility under standing orders from Texas community pharmacies and the efficacy of brief academic detailing on improving accessibility. UT Health San Antonio Center for Service Learning Annual Conference; San Antonio, TX; February 2019. **Best Poster Award & Blue Ribbon Award.**
7. *Mazin L, Hill LG, Evoy KE, Lawson KA.* Operation Naloxone: Multi-institutional opioid overdose prevention service learning for health professions students. UT College of Pharmacy Research Day; Austin, TX; April 2018.
6. *Groff L, Nguyen K, Tun K, Nguyen T, Hill LG, Evoy KE.* Operation Naloxone: Interprofessional overdose prevention service learning. UT College of Pharmacy Research Day; Austin, TX; April 2018.
5. *Mazin L, Hill LG, Evoy KE, Lawson KA.* Operation Naloxone: Multi-institutional opioid overdose prevention service learning for health professions students. Texas Society of Health-System Pharmacists Annual Seminar; Frisco, TX; April 2018.
4. *Groff L, Nguyen K, Tun K, Nguyen T, Hill LG, Evoy KE.* Operation Naloxone: Interprofessional overdose prevention service learning. Texas Society of Health-System Pharmacists Annual Seminar; Frisco, TX; April 2018. **Best Student Poster Award.**
3. *Tun K, Nguyen T, Groff L, Nguyen K, Evoy KE, Hill LG.* Operation Naloxone: Interprofessional overdose prevention service learning. UT Health San Antonio Center for Service Learning Annual Conference; San Antonio, TX; January 2018. **Best Poster Award.**
2. *Laguado SA, Sanchez JP, Hill LG.* Operation Naloxone: Overdose prevention service learning for student pharmacists. UT College of Pharmacy Research Day; Austin, TX; April 2017.
1. **Hill LG, Han JK.** Naloxone counseling for harm reduction and patient engagement. University of Pittsburgh Graduate Medical Education Leadership Conference; Pittsburgh, PA; February 2015.

Online Continuing Education & Podcasts

29. **Hill LG.** Pharmacy at the crossroads: Challenges and innovations in opioid use disorder treatment. Texas Opioid Training Initiative. May 2025.
28. **Hill LG.** Breaking issues in opioid use disorder treatment and harm reduction. <https://bit.ly/3Q9EylE>. Texas Opioid Training Initiative. September 2023.
27. **Hill LG, Garofoli MP.** Academia & addiction. Pharmacy Podcast Network: Pain Pod. <https://bit.ly/3dtFJCw>. August 2022.
26. **Hill LG.** Preventing opioid poisoning deaths: Naloxone dispensing and patient education pearls. Texas Pharmacy Association. <https://bit.ly/3Rfu35I>. July 2022.

25. Bratberg JP, Loera LJ, **Hill LG**. Barriers to treatment for opioid use disorder: Why aren't pharmacists stocking buprenorphine? Association for Multidisciplinary Education and Research in Substance Use and Addiction. <https://bit.ly/39cNxTA>. September 2021.
24. Jarrett JB, Jacobson AN, **Hill LG**. Overdose prevention outreach: Older adult & rural populations. American Association of Colleges of Pharmacy. <https://bit.ly/2QxPCUk>. April 2021.
23. **Hill LG**. Opioid use disorder in the COVID-19 era. <https://bit.ly/3af2gi1>. UT College of Pharmacy. August 2020.
22. **Hill LG**. From survival to recovery in opioid use disorder. <https://bit.ly/3snrgd4>. UT College of Pharmacy. July 2020.
21. **Hill LG**. Operation Naloxone: Opioid overdose prevention & response training. UT College of Pharmacy. <https://bit.ly/3g93e30>. June 2020.
20. Mackert M, Benz A, Carlton SB, **Hill LG**, Donovan E, Alport-Altillo B. Complying with the statewide mandate & using the PMP to provide patient-centered care. UT Dell Medical School. <https://txpmp.org/training>. March 2020.
19. **Hill LG**. Interactive harm reduction education for health professions students. University of Minnesota College of Pharmacy. <https://bit.ly/333XcKa>. December 2019.
18. **Hill LG**, Tirado CF. Person-centered care for opioid use disorder: Medication-assisted recovery 201. UT College of Pharmacy. <http://bit.ly/2TootT9>. December 2019.
17. **Hill LG**, Walsh D. Person-centered care for opioid use disorder: Medication-assisted recovery 101. UT College of Pharmacy. <http://bit.ly/2TootT9>. December 2019.
16. **Hill LG**, Hedenberg C. Person-centered care for opioid use disorder: Supportive behavioral interventions. UT College of Pharmacy. <http://bit.ly/2TootT9>. October 2019.
15. **Hill LG**, Holleran Steiker LK. Implementation of a collaborative model for opioid overdose prevention on campus. Higher Education Center for Alcohol and Drug Misuse Prevention and Recovery. <http://bit.ly/2XmEV6m>. October 2019.
14. **Hill LG**, Renfro ML, Loera LJ, Madni N, Nguyen N. The story of the opioid crisis. The Healthcare Scholar Audio Experience. <https://apple.co/2lyLP2e>. October 2019.
13. **Hill LG**, Tirado CF, Walsh D, Hedenberg C. Person-centered care for opioid use disorder. UT College of Pharmacy. <http://bit.ly/2TootT9>. September 2019.
12. **Hill LG**. Prescribing & dispensing naloxone is an essential component of opioid harm reduction. Opioid Response Network Texas Grand Rounds. September 2019.
11. **Hill LG**. Proactive strategies for opioid harm reduction. Texas Pharmacy Association. <https://bit.ly/2QqotCw>. September 2019.
10. **Hill LG**, Kinzly ML, Thibodeaux CR, Sledge D, Burwell A. Operation Naloxone: A harm reduction first model for addressing the opioid crisis. Texas Department of State Health Services. <http://bit.ly/2ENfYJ1>. May 2019.
9. **Hill LG**, Bratberg JP, Nesbit S, Ott C. The opioid crisis – Understanding its origins, implementing safety practices, and addressing stigma. Pharmacy Forward. <http://bit.ly/2LQQq3M>. April 2019.
8. **Hill LG**. From survival to recovery in opioid use disorder. UT College of Pharmacy. <http://bit.ly/2UFJTc9>. February 2019.
7. **Hill LG**, Nesbitt S. Opioid overdose crisis. Pharmacy Forward. <http://bit.ly/2EjB4PQ>. December 2018.
6. **Hill LG**, Holleran Steiker LK, Sanders MK. Recognition and response to opioid use and overdose in the school setting. UT School of Nursing. August 2018.
5. **Hill LG**, Holleran Steiker LK. Proactive overdose prevention on campus. NASPA Student Affairs Administrators in Higher Education. December 2017.
4. **Hill LG**, Shin J, Haines ST. Opioid stewardship strategies. iForumRx Website. <https://apple.co/2esm8zd>. November 2017.

3. **Hill LG**, Barnes JN, Holleran Steiker LK, Kinzly ML. Opioid harm reduction & overdose prevention. UT College of Pharmacy. August 2017.
2. **Hill LG**, Bratberg JP, Haines ST. Opioid safety and overdose prevention. iForumRx Website. <http://apple.co/2esm8zd>. October 2016.
1. **Hill LG**, Barnes JN. Naloxone harm reduction for Texas pharmacists. Texas Pharmacy Association. August 2016.

Invited Presentations

National Platforms

28. **Hill LG**. How do we solve the pharmacy buprenorphine problem? Veterans Affairs Quality Scholars; January 2025.
27. **Hill LG**, Jarrett JB, Chamberlin KW, Riccio KKC. Pain and addiction for the clinical pharmacist: Review and reassessment of the opioid epidemic, opioid use disorder, and non-opioid analgesics for pain. American College of Clinical Pharmacy Annual Meeting; Phoenix, AZ; October 2024.
26. **Hill LG**, Hursman A, Adeoye-Olatunde OA. Improving mental health through everyday patient accessible clinical services at your community-based pharmacy. American College of Clinical Pharmacy Annual Meeting; Phoenix, AZ; October 2024.
25. **Hill LG**. The pharmacy buprenorphine problem. National Institute on Drug Abuse Center for Substance Abuse Treatment; August 2024.
24. **Hill LG**, Strait MJ, Groves B, Chen C. Buprenorphine shortages and supporting patients in pharmacies: Perspectives from DEA and pharmacists. Centers for Disease Control and Prevention Opioid Rapid Response Program Opioid Preparedness National Partner Convening; Atlanta, GA; June 2024.
23. **Hill LG**. Overcoming pharmacy barriers to buprenorphine access. Providers Clinical Support System Medications for Opioid Use Disorder Clinical Roundtable; May 2024.
22. **Hill LG**, Freeman PR. Building bridges: Overcoming barriers to buprenorphine dispensing. American Pharmacists Association Annual Meeting; Orlando, FL; March 2024.
21. Skoy E, **Hill LG**, Sanaty Zadeh P. Open forum on pain management and substance use disorders. American Pharmacists Association Annual Meeting; Orlando, FL; March 2024.
20. **Torrez SB**, **Hill LG**. Overcoming pharmacy barriers to buprenorphine access through education and communication. Ophelia Health, Inc.; March 2024.
19. **Hill LG**. Breaking issues in opioid use disorder treatment and harm reduction. American College of Clinical Pharmacy Community-Based Practice and Research Network; September 2023.
18. **Hill LG**. Any positive change: A compassionate and effective approach for people who use drugs. Imperva, Inc.; August 2023.
17. **Hill LG**. Family Medicine Grand Rounds: Harm reduction strategies for institutional practice. University of Pittsburgh Medical Center; November 2022.
16. **Hill LG**. How do we solve the pharmacy buprenorphine problem? Veterans Affairs Quality Scholars; October 2022.
15. **Hill LG**, Ostrach B, Joudrey P, Werremeyer A. Health services research: Buprenorphine dispensing barriers. The Role of Community Pharmacies in Treating Opioid Use Disorder: Defining the National Institute on Drug Abuse Clinical Trials Network Research Roadmap; May 2022.
14. **Hill LG**. Implementation of a collaborative model for opioid overdose prevention on campus. Oregon Prevention Coalition; March 2022.
13. Britt A, Rucker J, Steenbergh S, Tilley J, **Hill LG**. Guidance for incorporating the perspectives of people with lived experience. Association for Multidisciplinary Education and Research in Substance Use and Addiction Annual Meeting; November 2021.

12. **Hill LG**, Zagorski CM. Increasingly powerful opioid antagonists are not necessary. The University of Alabama at Birmingham; November 2021.
11. **Hill LG**, Pawasauskas J, Bratberg J. Opioid use disorder: Where we have been and where we are going. American College of Clinical Pharmacy Annual Meeting; October 2021.
10. **Hill LG**, Ventricelli DJ, Church AF, Palombi L. Annual business meeting of the Substance Use Disorder SIG. American Association of Colleges of Pharmacy Annual Meeting; July 2021.
9. Marino R, **Hill LG**, Kinkle B. Intro to harm reduction for health professions students. University of Iowa Carver College of Medicine; Iowa City, IA; March 2021.
8. Palombi L, **Hill LG**, Ventricelli DJ, Tran TH. Annual business meeting of the Substance Use Disorder SIG. American Association of Colleges of Pharmacy Annual Meeting; Long Beach, CA; July 2020.
7. **Hill LG**. Interactive harm reduction education for health professions students. University of Minnesota Academic Health Center Research Seminar; Duluth, MN; December 2019.
6. **Hill LG**, Bernitz MJ, Smith A. Preventing overdoses on college campuses: Developing a comprehensive overdose program. U.S. Office of National Drug Control Policy. Washington, D.C.; November 2019.
5. Tran TH, Palombi L, **Hill LG**, Koh-Knox CP. Annual business meeting of the Substance Use Disorder SIG. American Association of Colleges of Pharmacy Annual Meeting; Chicago, IL; July 2019.
4. **Hill LG**, Jacobson AN. Naloxone to the rescue: The pharmacist's emerging role in preventing opioid overdose. American Pharmacists Association Annual Meeting & Exposition; Seattle, WA; March 2019.
3. Clements JN, **Hill LG**, Kane-Gill SL, Cristiani CA, Wicke C, Hough AR, Wang F. Population health and telemedicine approaches to commonly encountered conditions in ambulatory care. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 2018.
2. **Hill LG**. Operation Naloxone: Opioid overdose prevention service learning. University of Kentucky College of Pharmacy; Lexington, KY; September 2018.
1. **Hill LG**, Hearod K, Botticelli M, Soriano D, Ramirez L, Sledge D, Ingham J. Youth opioid harm prevention. <https://youtu.be/NMUKbpotCzk>. SAMHSA National Prevention Week Town Hall; Austin, TX; May 2018.

Regional Workshops

24. **Hill LG**. Facilitating MOUD access through alignment with the PhARM-OU D Guideline. Allegheny County Opioid Stewardship Pharmacy Collaborative; January 2026.
23. **Hill LG**. Pharmacy barriers to buprenorphine dispensing. Texas Society of Addiction Medicine Quarterly Meeting; June 2022.
22. **Loera LJ**, **Hill LG**. Optimizing collaboration to enhance treatment access. Texas Substance Use Symposium; March 2022.
21. **Hill LG**. Pharmacist collaboration to improve substance use disorder treatment and harm reduction access. Texas Medication for Opioid Use Disorder Community of Practice ECHO. December 2021.
20. **Hill LG**. Syringe services programs: A vital tool for Texas. Texas Health and Human Services Commission Institute; August 2021.
19. **Hill LG**, Perez V. Naloxone prescribing and distribution in the hospital. Texas Medications for Opioid Use Disorder Support Hospital Opioid Use Disorder Treatment ECHO; August 2021.
18. **Hill LG**, Zagorski CM. Operation Naloxone: An interprofessional service-learning program. Texas Interprofessional Education Consortium; May 2021.

17. **Hill LG**, Mackert M. Engaging with the prescription monitoring program to provide better patient care. Texas Substance Use Symposium; April 2021.
16. **Hill LG**, Cleveland LM, Zagorski CM. A harm reduction approach to overdose prevention. University of Texas Health San Antonio; San Antonio, TX; August 2020.
15. **Hill LG**. Operation Naloxone training for pharmacy faculty and students. Texas Tech University Health Sciences Center School of Pharmacy; Dallas, TX; April 2020.
14. **Hill LG**. Addressing overdose risk in patients with opioid use disorder. Texas Medication for Opioid Use Disorder Community of Practice ECHO. January 2020.
13. **Hill LG**. Operation Naloxone training for health professions faculty and students. University of North Texas Health Science Center; Fort Worth, TX; January 2020.
12. **Hill LG**, Rasu RS. Operation Naloxone training for high school teachers and students. Westlake Academy; Westlake, TX; January 2020.
11. **Hill LG**. Training community pharmacists to engage patients at risk for opioid overdose. The University of Texas at El Paso School of Pharmacy; El Paso, TX; July 2019.
10. **Hill LG**. Establishing opioid use disorder treatment services in a federally qualified health center. San Vicente Family Health Center; El Paso, TX; June 2019.
9. Luk J, **Hill LG**. Interprofessional learning and practice. UT Dell Medical School Distinction Program for Care Transformation; Austin, TX; June 2019.
8. **Hill LG**, Hamilton-Solum P, Jones-Swann L, Schnyer R, Bottner R. Changing the language of addiction. UT Center for Health Interprofessional Practice and Education Showcase; Austin, TX; May 2019.
7. **Hill LG**. Hospital-based naloxone dispensing for pharmacists. UT Dell Seton Medical Center; Austin, TX; April 2019.
6. **Hill LG**. Achieving overdose preparedness on campus. UT System Collegiate Recovery Programs Annual Seminar; Austin, TX; April 2018.
5. **Hill LG**, *Sanchez JP*. Operation Naloxone training for pharmacy faculty and students. Texas A&M Health Science Center College of Pharmacy; College Station, TX; February 2018.
4. **Hill LG**, Kinzly ML. Harm reduction workshop for healthcare professionals. Superior HealthPlan Pain and Opioid Use Disorder Summit; Austin, TX; February 2018.
3. **Hill LG**. Overdose prevention basics for clinical staff. CommUnityCare Clinical Supervisors Seminar; Austin, TX; January 2018.
2. **Hill LG**, *Sanchez JP*. Operation Naloxone training for pharmacy faculty and students. The University of Houston College of Pharmacy; Houston, TX; October 2017.
1. **Hill LG**. Operation Naloxone training for health professions faculty and students. UT Health San Antonio; San Antonio, TX; September 2017.

Regional Platforms

59. **Hill LG**. Pharmacy at the crossroads: Challenges and innovations in opioid use disorder treatment. UPMC Health Plan Pharmacy CE Series; August 2025.
58. **Hill LG**. A legacy of love and connection. Communities for Recovery Lifebuilder Luncheon; Austin, TX; May 2025.
57. **Hill LG**. Pharmacy at the crossroads: Challenges and innovations in opioid use disorder treatment. Geisinger College of Health Sciences Pharmacy Grand Rounds; April 2025.
56. **Hill LG**. Pharmacy at the crossroads: Challenges and innovations in opioid use disorder treatment. Pitt School of Medicine Bridging Connections in Addiction Research Seminar; March 2025.
55. **Hill LG**. Breaking issues in opioid use disorder treatment and harm reduction. UT College of Pharmacy Pharmacy Practice Seminar; Austin, TX; September 2023.
54. Kertesz S, **Hill LG**. 2022 CDC guideline for prescribing opioids for pain. Texas Substance Use Symposium; February 2023.

53. **Hill LG.** Recovery support peer services fellows: Ask a pharmacist! UT Health Houston School of Public Health; November 2022.
52. Karns-Wright TE, Zagorski CM, **Hill LG**, Potter JS. Improving access to medications for opioid use disorder in Texas. Texas Health & Human Services Commission; September 2022.
51. **Hill LG.** Preventing opioid poisoning deaths: Naloxone dispensing and patient education pearls. Texas Pharmacy Association; Houston, TX; July 2022.
50. **Hill LG.** Productive engagement with people who use drugs is possible with a harm reduction mindset. Texas Tech University Health Sciences Center; June 2022.
49. **Hill LG.** Productive engagement with people who use drugs is possible with a harm reduction mindset. Golden Crescent Substance Use Recovery Symposium; Valencia, TX; May 2022.
48. **Hill LG.** An interview with Dr. Lucas Hill. Rice University Substance Use Speaker Series; May 2022.
47. Potter JS, Keller A, Ramirez L, Strey K, **Hill LG.** Substance use interventions in Texas: Lessons learned and future directions. Texas Substance Use Symposium; March 2022.
46. Zagorski CM, **Hill LG.** The real & imagined risks of novel synthetic drugs. Texas Substance Use Symposium; February 2022.
45. **Loera LJ, Hill LG.** Myth versus reality: What every pharmacist needs to know about buprenorphine for opioid use disorder. UT College of Pharmacy Pharmacy Practice Seminar; Austin, TX; September 2021.
44. **Hill LG.** Productive engagement with people who use drugs is possible with a harm reduction mindset. Texas Tech University Health Sciences Center; July 2021.
43. **Hill LG, Bottner R.** Naloxone prescribing & standing order guidance for Texas hospitals. Texas Health & Human Services Commission; June 2021.
42. **Hill LG.** Meet people where they are: Substance use and the pedagogy of harm reduction in healthcare. Texas Interprofessional Education Consortium; May 2021.
41. **Hill LG.** Five common myths about the opioid crisis. University of North Texas Health Science Center; Fort Worth, TX; February 2021.
40. **Hill LG.** Opioid use disorder controversies for public health professionals. UT Health Houston School of Public Health; Houston, TX; October 2020.
39. **Hill LG.** From survival to recovery in opioid use disorder. Superior HealthPlan Substance Use Disorder Summit; Austin, TX; October 2020.
38. **Hill LG.** From survival to recovery in opioid use disorder. Superior HealthPlan Pharmacy Summit; Austin, TX; August 2020.
37. **Hill LG.** Opioid harm reduction in the age of fentanyl. University of Texas Medical Branch at Galveston Family Medicine Grand Rounds; Galveston, TX; June 2020.
36. **Hill LG.** Turning another frustrating mandate into lemonade: Effective use of the Texas prescription monitoring program. CommUnityCare Department of Education & Research; Austin, TX; June 2020.
35. **Hill LG.** Best practices for opioid harm reduction in oncology. Macy Cancer Center Practical Applications of New Agents in Oncology Conference; San Antonio, TX; February 2020.
34. **Hill LG.** Opioid harm reduction in the age of fentanyl. UT Dell Medical School Substance Use Disorder Grand Rounds; Austin, TX; December 2019.
33. **Hill LG, Bottner R, Mason KR, Moriates C, Yagoda N.** Guidelines to practice: Developing broad systems of care for the treatment of opioid use disorder. UT College of Pharmacy Psychiatric Pharmacotherapy Update; Austin, TX; October 2019.
32. **Hill LG.** Neurobiology and treatment of opioid use disorder. UT College of Pharmacy Psychiatric Pharmacotherapy Update; Austin, TX; October 2019.

31. **Hill LG.** Engaging the Texas prescription monitoring program to support patient health. Austin Area Society of Health-System Pharmacists Annual Pharmacy Seminar; Round Rock, TX; October 2019.
30. **Hill LG,** Tirado CF, Walsh D, Hedenberg C. Person-centered care for opioid use disorder. UT College of Pharmacy Pharmacy Practice Seminar; Austin, TX; September 2019.
29. **Hill LG.** From survival to recovery in opioid use disorder. UT College of Pharmacy Pharmacy Practice Seminar; Austin, TX; September 2019.
28. **Hill LG.** Proactive strategies for opioid harm reduction. H-E-B Pharmacy Conference; San Antonio, TX; September 2019.
27. **Hill LG.** Engaging the Texas prescription monitoring program to support patient health. Texas Nurse Practitioners Annual Conference; Austin, TX; September 2019.
26. **Hill LG.** Proactive strategies for opioid harm reduction. Texas Pharmacy Association Annual Conference; Irving, TX; August 2019.
25. **Hill LG,** Kinzly ML, Thibodeaux CR, Sledge D, Burwell A. Operation Naloxone: A harm reduction first model for addressing the opioid crisis. Texas Department of State Health Services; Austin, TX; May 2019.
24. **Hill LG,** Karam-Hage M, Quintanilla R. Team care for SUD and integration of HIT and Project ECHO. Texas Association of Community Health Centers Clinical Conference; Austin, TX; April 2019.
23. **Hill LG.** Mentoring resident scholarship. CommUnityCare Preceptor Development Conference; Austin, TX; October 2018.
22. **Hill LG,** Crowe D, Peyson R, Peoples M. Local innovations to address the opioid crisis. Alliance for Innovation: Transforming Local Government Conference; Austin, TX; October 2018.
21. **Hill LG.** From survival to recovery in opioid use disorder. UT College of Pharmacy Psychiatric Pharmacotherapy Update; Austin, TX; October 2018.
20. **Hill LG.** Addressing the opioid crisis by focusing on harm reduction. UT Dell Medical School Integrated Behavioral Health Scholars Program; Austin, TX; September 2018.
19. **Hill LG,** Young VS. Professional roles, responsibilities, stereotypes, and implicit biases. UT Dell Medical School Integrated Behavioral Health Scholars Program; Austin, TX; September 2018.
18. **Hill LG,** Holleran Steiker LK, Sanders MK. Recognition and response to opioid use and overdose in the school setting. UT School of Nursing School Nurse Competency Fair and Conference; Austin, TX; August 2018.
17. Barnes JN, **Hill LG.** Opioid overdose: A risk factor review. Superior HealthPlan Pharmacy Summit; Austin, TX; August 2018.
16. **Hill LG.** Innovative opioid overdose prevention. Texas Society of Addiction Medicine Interprofessional Addiction Institute; San Antonio, TX; July 2018.
15. **Hill LG,** Botticelli M, Beletsky L, Ramirez L, Kinzly ML, Tirado C. Opioid misuse prevention and harm reduction strategies for youth. UT Youth Substance Misuse Pop-Up Institute; Austin, TX; May 2018.
14. **Hill LG.** Opioid use and youth: A harm reduction focus. UT Youth Substance Misuse Pop-Up Institute; Austin, TX; May 2018.
13. **Hill LG,** Holleran Steiker LK, Potter JS. Opioid discovery session. UT System 51st Chancellor's Council Annual Meeting & Symposium; Austin, TX; April 2018.
12. **Hill LG,** Ramirez L. Evidence-based policies to confront the opioid crisis. Students for Sensible Drug Policy Southwest Regional Conference; Austin, TX; December 2017.
11. **Hill LG.** Opioid harm reduction in the age of fentanyl. UT Dell Medical School Internal Medicine Grand Rounds; Austin, TX; October 2017.
10. **Hill LG.** Curbing the epidemic of opioid overdose. UT College of Pharmacy Homecoming; Austin, TX; October 2017.

9. **Hill LG.** Opioid harm reduction for community pharmacists. UT College of Pharmacy Pharmacy Practice Seminar; Austin, TX; September 2017.
8. **Hill LG.** Compassionate opioid harm reduction initiatives in Texas. Texas Overdose Awareness Day; Austin, TX; August 2017.
7. **Hill LG.** Compassionate opioid harm reduction initiatives in Texas. Williamson County Overdose Awareness Day; Round Rock, TX; August 2017.
6. **Hill LG,** Hinds A. Applying student rotation tools in ambulatory care rotations. UT College of Pharmacy Preceptor Conference; Austin, TX; August 2017.
5. **Hill LG,** Holleran Steiker LK, Marteney S. Operation Naloxone: Interprofessional collaboration to prevent opioid overdose. Texas HHSC Neonatal Abstinence Syndrome Symposium; San Antonio, TX; June 2017.
4. **Hill LG,** Kinzly ML. Preventing drug overdoses in transitional housing. Texas Homeless Network Supportive Housing = Healthcare Conference; Austin, TX; May 2017.
3. **Hill LG,** *Laguado SA.* Operation Naloxone: Novel overdose prevention training. UT College of Pharmacy Dean's Advisory Council; Austin, TX; April 2017.
2. **Hill LG.** Counseling renal patients regarding cannabis & supplement use. UPMC Shadyside Dialysis Education Conference; Pittsburgh, PA; May 2015.
1. **Hill LG,** Sphar BE. Cannabis as medicine: Practical considerations. University of Pittsburgh Family Medicine Refresher Course; Pittsburgh, PA; March 2015.

Internal Workshops & Platforms

32. **Hill LG.** My path + your opportunities in addiction research & practice. UT American Association of Psychiatric Pharmacists; Austin, TX; October 2023.
31. **Hill LG.** Scholarship metrics, profiles, & pearls. UT College of Pharmacy Teaching and Leadership Fellows Program; Austin, TX; January 2023.
30. **Hill LG.** Scholarship metrics, profiles, & pearls. UT College of Pharmacy Writer's Block; Austin, TX; July 2022.
29. **Hill LG.** Key opioid-related pearls for addiction psychiatry fellows. UT Dell Medical School; Austin, TX; August 2021.
28. **Hill LG.** Operation Naloxone training for medical students. UT Dell Medical School; Austin, TX; June 2021.
27. **Hill LG.** Operation Naloxone training for medical students. UT Dell Medical School; Austin, TX; March 2020.
26. **Hill LG,** Zagorski CM. Opioid overdose response training for law enforcement officers. UT Police Department; Austin, TX; January 2020.
25. **Hill LG.** Engaging the Texas prescription monitoring program to support patient health. UT University Health Services Continuing Medical Education Conference; Austin, TX; November 2019.
24. **Hill LG.** Opioid use disorder and harm reduction in the context of homelessness. UT Lyndon B. Johnson School of Public Affairs; Austin, TX; October 2019.
23. **Hill LG.** Operation Naloxone training for medical students. UT Dell Medical School; Austin, TX; April 2019.
22. **Hill LG.** My path to becoming ambulatory care clinical faculty at the UTCOP. Longhorn Pre-Pharmacy Association, Austin, TX; February 2019.
21. **Hill LG.** The pharmacist's role in patient care. UT School of Nursing; Austin, TX; October 2018.
20. **Hill LG.** Community-based opioid overdose prevention. UT Waggoner Center for Alcohol and Addiction Research; Austin, TX; September 2018.
19. **Hill LG.** Operation Naloxone: Preventing drug overdose deaths. UT University Lecture Series; Austin, TX; April 2018.

18. Date MK, **Hill LG**, Morgan S, Delaney M. Interprofessional complex chronic disease workshop. UT Primary Care Progress; Austin, TX; March 2018.
17. **Hill LG**. Professional development fireside chat. UT Phi Lambda Sigma Pharmacy Leadership Society; Austin, TX; February 2018.
16. Messing B, **Hill LG**, Baker J, Velasquez M, Marinelli M. The addicted brain: A conversation about alcohol and drug addiction. UT College of Natural Sciences Department of Neuroscience; Austin, TX; January 2018.
15. **Hill LG**, *Mazin L*. Operation Naloxone training for social work students. UT School of Social Work; Austin, TX; November 2017.
14. **Hill LG**. CV development workshop. UT Phi Delta Chi Pharmacy Fraternity; Austin, TX; October 2017.
13. **Hill LG**. The pharmacist's role in patient care. UT School of Nursing; Austin, TX; October 2017.
12. Holleran Steiker LK, **Hill LG**. A conversation about opioid recovery. UT Center for Students in Recovery Seminar on Addiction and Recovery; Austin, TX; September 2017.
11. **Hill LG**, Barnes JN. Operation Naloxone training for medical students and faculty. UT Dell Medical School; Austin, TX; August 2017.
10. **Hill LG**, *Garcia L*. Operation Naloxone training for resident advisors. UT Resident Advisor Orientation; Austin, TX; August 2017.
9. **Hill LG**. The pharmacist's role in identifying and addressing illicit drug use. UT Student Pharmacist Recovery Network; Austin, TX; April 2017.
8. **Hill LG**. A new practitioner's viewpoint on leadership in pharmacy. UT Phi Lambda Sigma Pharmacy Leadership Society; Austin, TX; March 2017.
7. **Hill LG**. Preparing for and evaluating PGY1 and PGY2 residency opportunities. UT Student College of Clinical Pharmacy; Austin, TX; January 2017.
6. **Hill LG**. Opioid harm reduction: A pharmacist's perspective. UT Center for Students in Recovery Seminar on Addiction and Recovery; Austin, TX; November 2016.
5. **Hill LG**. The pharmacist's role in patient care. UT School of Nursing; Austin, TX; October 2016.
4. **Hill LG**, Barnes JN, Holleran Steiker LK, Kinzly ML. Operation Naloxone training for police officers. UT Police Department; Austin, TX; September 2016.
3. **Hill LG**, Biberdorf K, Carpenter Q, Rhodes D. Insights for non-tenure track faculty. UT New Faculty Symposium; Austin, TX; August 2016.
2. **Hill LG**, Barnes JN. Operation Naloxone training for resident advisors. UT Resident Advisor Orientation; Austin, TX; August 2016.
1. **Hill LG**. Introduction to ambulatory care clinical pharmacy practice. UT Student College of Clinical Pharmacy; Austin, TX; January 2016.

Advising

Graduate & Honors Students

Claire Zagorski (PhD): Co-Advisor	2022–Present
Rana Zalmai (PhD): Co-Advisor	2021–2024
Sorina Torrez (MS): Co-Advisor	2022–2024
Hannah McCullough (MPH): Practicum Advisor	2022–2023
Kelley White (PharmD): Honors Research Advisor	2022
Taylor Britton (MPH): Practicum Advisor	2021–2022
Shiyu Zhang (PhD): Dissertation Committee Member	2020–2021
Lubna Mazin (PharmD): Honors Research Advisor	2019

National Awards & Internships

Rana Zalmai: AFPE Fellowship in Health Outcomes Disparities	2024
Hannah McCullough: USPHS Public Health Excellence Award	2024
Johann Lin: Tarsus Pharmaceuticals Medical Affairs Internship	2024
Amber Tran: AMERSA Growing a Diverse Workforce Award	2023
Lindsey Loera: ACCP Research Fellowship Best Poster	2021
Lindsey Loera: AACP Best Poster by a Resident, Fellow, or Postdoc – Finalist	2021
Mandy Renfro: USPHS Public Health Excellence Award – Top Recipient	2020
Lindsey Loera: USPHS Public Health Excellence Award	2019
Lubna Mazin: USPHS Public Health Excellence Award	2018
Mandy Renfro: AMCP Foundation / Pfizer Managed Care Internship	2018
John Patrick Sanchez: ACCP Student Chapter of the Year Award	2017
Andrea Laguado: USPHS Public Health Excellence Award	2017
Andrea Laguado: CPNP Research Trainee Award – Finalist	2017

Regional Awards & Internships

Claire Zagorski: UT WCAAR Bruce/Jones Fellowship in Addiction Biology	2023–2026
Hannah McCullough: UT Center for Health IPE Best Visual Poster Award	2023
Kelley White: Baylor Scott & White Health Longitudinal APPE	2021–2022
Lindsey Loera: UT College of Pharmacy Best Postdoctoral Fellow Abstract Award	2021
Sorina Torrez: UT College of Pharmacy Benjamin Reed Leader in Pharmacy Award	2021
Caitie Labay: Methodist Hospital Longitudinal APPE	2019–2020
Lisa Garcia: UT College of Pharmacy Best PharmD Program Poster Award	2019
Michelle Tran: UT College of Pharmacy Best PharmD Program Abstract Award	2019
William Godinez: UT Health San Antonio Best Poster Award	2019
William Godinez: UT Health San Antonio Blue Ribbon Award	2019
Lindsey Groff: TSHP Best Student Poster Award	2018
Andrea Laguado: Texas Friar Society Membership	2018
Khine Tun: UT Health San Antonio Best Poster Award	2018
Andrea Laguado: TPA Generation Rx Champion Award	2017
John Patrick Sanchez & Andrea Laguado: UT Pharmacy Council Service Event of the Year	2017

Residencies & Fellowships

Sofia Garcia: Indian Health Service Alaska Native Medical Center	2025
Kris Rodriguez: Parkland Health and Hospital System	2025
Emily Johnson: Veterans Affairs Aurora Health Care System	2025
Shannon Mayberry: Emory University Hospital	2025
Sabrina Guerra: Baylor Health Enterprises	2025
Grace Ukazim: University of Maryland Baltimore Washington Medical Center	2024
Berkin Kutluk: University of Chicago Medicine Ingalls Memorial Hospital	2024
Amber Tran: Saint Francis Health System	2024
Hannah McCullough: University of Virginia Health	2024
Kami Johnston: Eastern Colorado Veterans Healthcare System	2023
Taylor Britton: Intermountain Medical Center	2023
Megan Yeung: New York Presbyterian Hospital	2023
Michaela Clague: Indiana University Health	2023
Amy Le: South Texas Veterans Health Care System	2023
Morgan Murchison: Central Texas Veterans Health Care System	2023
Sorina Torrez: UT College of Pharmacy	2022
Kelley White: Central Texas Veterans Health Care System	2022
Caitlin Vogt: Veterans Affairs Portland Health Care System	2021

Madelynn Burgess: South Texas Veterans Health Care System	2021
Amanda Charles: Central Texas Veterans Health Care System	2021
Mandy Renfro: AbbVie Pharmacyclics, Medical Affairs	2020
Lindsey Loera: UT College of Pharmacy	2020
Meghan Ha: Tabula Rasa HealthCare	2020
Lisa Garcia: University Medical Center of El Paso	2020
Lubna Mazin: Nationwide Children's Hospital	2019
John Patrick Sanchez: MD Anderson Cancer Center	2018
Mohammad Abotteen: Debakey Veterans Affairs Medical Center	2018
Qasim Adil: Debakey Veterans Affairs Medical Center	2018
Andrea Laguado: Banner Health University Medical Center	2018
Diem Ho: Valley Baptist Medical Center	2018
Julie John: Texas Tech University Health Science Center	2017

Student Organizations

Faculty Co-Advisor: College of Psychiatric & Neurologic Pharmacists	2016–2022
Faculty Co-Advisor: Primary Care Progress	2017–2019
Faculty Co-Advisor: Student College of Clinical Pharmacy	2015–2017

Faculty Mentorship

Scholarship Mentor – Lindsey Loera	2022–Present
Scholarship Mentor – Denise Kelley	2023–2024
Scholarship Mentor – Kathryn Litten	2022–2024
Teaching Mentor – Samantha Catanzano	2021–2024

Service

National & Regional Organizations

Yale Program in Addiction Medicine & Foundation for Opioid Response Efforts	
Member: National Methadone Access & Quality Commission (NMAQC)	2025–2028
Association for Multidisciplinary Education and Research in Substance Use and Addiction	
Treasurer: Board of Directors	2024–2026
Member: Governance Committee	2025–2026
Member: Development Committee	2024–2026
Co-Chair: Conference Abstract Committee	2023–2026
Mentor: Mentorship Program	2025–2026
Chair: Fellowship Task Force	2025–2026
Member-at-Large: Board of Directors	2023–2024
Member: Advocacy Task Force	2023
Veterans Affairs Pittsburgh Healthcare System	
Member: Interprofessional Addiction Fellowship Advisory Board	2024–Present
Texas Targeted Opioid Response	
Co-Chair: Texas Substance Use Symposium	2020–2024
Chair: Texas Opioid Training Initiative	2017–2024
American Pharmacists Association	
Lead Investigator: Opioid Response Network Buprenorphine Access Study	2021–2023
Member: Generation Rx Award of Excellence Selection Committee	2020–2021
American Association of Colleges of Pharmacy	
Chair: Substance Use Disorders Special Interest Group	2019–2022
Member: Special Committee on Substance Use & Pharmacy Education	2019–2021
Member: Advocacy Committee	2016–2017

American College of Clinical Pharmacy	
Member: Alliance for Addiction Payment Reform Issue Brief	2021–2022
Faculty Panel Chair: ACSAP Neurologic Care and Pain Management	2018–2019
Member: Educational Affairs Committee	2016–2017
Faculty Liaison: The University of Texas at Austin	2015–2017
Chair: Ambulatory Care PRN Resident Committee	2015–2016
Member: National Resident Advisory Committee	2014–2015
Vice-Chair: Ambulatory Care PRN Resident Committee	2014–2015
Member: Ambulatory Care PRN Resident Committee	2013–2014
National Institute on Drug Abuse	
Co-Chair: Clinical Trials Network Workshop on Pharmacist Collaboration	2022
Substance Abuse and Mental Health Services Administration	
Member: Policy Priority Panel on Buprenorphine Access in Pharmacy Settings	2022

Editorial Service

Member: Journal of the American College of Clinical Pharmacy Editorial Board	2021–2026
Top High-Quality Peer Reviewer: Journal of Managed Care & Specialty Pharmacy	2026
Member: Health Affairs Overdose Crisis Theme Issue Planning Committee	2024–2025
Outstanding Peer Reviewer: Journal of the American Pharmacists Association	2021
Outstanding Peer Reviewer: Journal of the American Pharmacists Association	2019
Member: iForumRx Editorial Board	2016–2018

Peer Review

Substance Use and Addiction Journal (Substance Abuse)	2020, 2025–2026
Drug and Alcohol Dependence	2021, 2024, 2025–2026
JAMA Network Open	2026
Journal of the American College of Clinical Pharmacy	2018–2025
Harm Reduction Journal	2023, 2025
Drug and Alcohol Dependence Reports	2025
JAMA Pediatrics	2025
ACCP Pharmacotherapy Self-Assessment Program	2025
Health Affairs	2025
Journal of Managed Care and Specialty Pharmacy	2025
Journal of School Health	2025
East Tennessee State University Bill Gatton College of Pharmacy Promotion Dossier	2024
Journal of the American Medical Association	2024
American Journal of Public Health	2024
Journal of Addiction Medicine	2023
Annals of Internal Medicine	2023
AMERSA Annual Conference Abstracts	2023
ACCP Ambulatory Care Self-Assessment Program	2021–2022
Journal of the American Pharmacists Association	2016–2022
University of Miami Miller School of Medicine Promotion Dossier	2022
American Journal of Pharmaceutical Education	2019–2021
National Institute on Drug Abuse Clinical Trials Network	2021
University of Minnesota College of Pharmacy Promotion Dossier	2021
Substance Abuse Treatment, Prevention, and Policy	2021
UT System ConTex Collaborative Research Grants Competition	2020
ACCP Pain Management and Addiction Medicine	2020
iForumRx	2018–2020
Journal of American College Health	2019

Research in Social and Administrative Pharmacy	2019
Drug and Alcohol Review	2019
PLOS ONE	2018
Journal of Pediatric Pharmacology and Therapeutics	2018
Pharmacotherapy	2016–2018
ACCP Pharmacotherapy Review and Recertification Course	2015–2017
Currents in Pharmacy Teaching and Learning	2015–2017
Family Medicine	2016
Pharmacy	2015–2016
Evidence-Based Practice	2015
International Journal of Psychiatry in Medicine	2014

University of Pittsburgh

Leadership

Steering Committee: Bridging Connections in Addiction Research	2025–Present
Steering Committee: Safer Use Research and Education Center	2025–Present

Membership

Seminar Committee: Bridging Connections in Addiction Research	2025–Present
Symposium Committee: Bridging Connections in Addiction Research	2025–Present

The University of Texas at Austin College of Pharmacy

Leadership

Scholarship Chair: Pharmacy Practice Division Leadership Board	2022–2024
Chair: Interprofessional Education Subcommittee	2019–2021
Chair: Person-Centered Care for Opioid Use Disorder Committee	2020–2021
Chair: Pharmacy Practice Division Ambulatory Care Search Committee	2018–2019
Vice-Chair: Interprofessional Education Subcommittee	2016–2019

Membership

Pharmaceutical Science Graduate Studies Committee	2024–Present
Translational Science Graduate Studies Committee	2023–Present
Advancing Research & Scholarship Committee	2022–2024
William Arlyn Kloesel Outstanding Preceptor Award Selection Committee	2018–2024
Faculty Development & Wellbeing Committee	2021–2023
Building Our Own Talent Program Advisory Committee	2020–2021
Strategic Plan Working Group for Research	2020–2021
Hospital Practice Seminar Committee	2020–2021
Non-Tenure-Track Promotion Review Committee	2021
Curriculum Committee	2019–2021
Pharmacy Practice Division Scholarship Working Group	2019–2021
Departmental Review of Human Subjects Research Committee	2019–2020
AACP Weaver Award Application Committee	2019–2020
Student Success Committee	2017–2019
CommUnityCare Resident Research Committee	2016–2019
CommUnityCare Residency Advisory Committee	2016–2019
Professional Development Committee	2016–2017
Residencies Committee	2015–2017
Financial Aid Committee	2015–2017
CommUnityCare Drug Therapy Management Committee	2015–2016

Volunteerism

Prospective Student Interviews	2022–2024
PharmD Convocation	2016–2023

White Coat Ceremony	2016–2022
New Student Orientation	2016–2021
ExploreUT	2017–2020
P4 Milestone Remediation Panel	2020
P4 Milestone Exam Reviewer	2016–2019
Pre-Pharmacy Association Luncheon	2017–2018

The University of Texas at Austin

Centers & Institutes

Affiliate: Addiction Research Institute (ARI)	2023–2024
Affiliate: Waggoner Center for Alcohol and Addiction Research (WCAAR)	2022–2024
Fellow: Center for Health Interprofessional Practice and Education (CHIPE)	2018–2024
Affiliate: Center for Health Communication (CHC)	2017–2024
Member: Youth Substance Misuse Pop-up Institute	2017–2018

Committee Membership

Member: Opioid Response Consortium	2018–2024
Member: CHIPE Interprofessional Curriculum Committee	2020–2023
Member: Dell Seton Medical Center Naloxone Standing Order Committee	2018–2021
Member: Wellness Network Substance Use Safety Committee	2015–2019

Campus Events

Co-Sponsor: Storytelling together for social change	2024
Host: What is heroin anymore? Chemical insights for public health.	2022

Volunteerism

Interprofessional Health Showcase	2019–2024
Health Sciences Summer Camp	2018–2020
Annual Campus Drug Takeback Event	2017–2019
National Public Health Week	2016–2019
Interprofessional Poverty Simulation	2017–2018
Office of Health Professions Student Networking Event	2015–2016

Teaching

University of Pittsburgh School of Pharmacy

Course Coordination

Intro US Healthcare System & Pharmaceuticals (3306)	Fall 2025
-----------------------------------------------------	-----------

Didactic Instruction

Intro US Healthcare System & Pharmaceuticals (3306)	Fall 2025–Present
Case Conference Series 4 (5227)	Spring 2026
Nonprescription Therapies and Self-Care Practice (5210)	Fall 2025
Pharmacotherapy III: Acute Gouty Arthritis	2015
Critical Literature Analysis	2015

Research Instruction

Special Topics (5851)	Fall 2025
-----------------------	-----------

Experiential Precepting

Ambulatory Care Advanced Pharmacy Practice Experience	2013–2015
Dietary Supplement Service Learning Program	2013–2015

The University of Texas at Austin College of Pharmacy

Post-Graduate Instruction

Co-Director: UT Pharmacotherapy Residency	2022–2024
Director: PhARM Program Fellowship	2020–2022

Preceptor: CommUnityCare Ambulatory Care Residency	2015–2020
Course Coordination	
Pharmacotherapeutics of Pain & Addiction (291)	2021–2023
Foundations for Interprofessional Collaborative Practice I (191U)	2018–2023
Foundations for Interprofessional Collaborative Practice II (191V)	2019–2022
Non-Prescription Pharmacotherapeutics II Lab (182P)	2018
Course Co-Coordination	
Foundations for Interprofessional Collaborative Practice II (191V)	2023
Pharmacotherapeutics III: Pain & Addiction Module (685F)	2018–2019
Foundations of Professional Development V/VI (283S/T)	2018–2019
Foundations of Professional Development I/II (281C/D)	2016–2018
Advanced Evidence-Based Practice (295R)	2016
Experiential Precepting	
Addiction Medicine Advanced Pharmacy Practice Experience (693E)	2019–2024
Operation Naloxone Introductory Pharmacy Practice Experience	2016–2024
Academic Advanced Pharmacy Practice Experience (693E)	2020
Ambulatory Care Advanced Pharmacy Practice Experience (693C)	2015–2019
Didactic Instruction	
Pharmacy Practice Lab II (182V)	2021–2024
Foundations for Interprofessional Collaborative Practice V/VI (193U/V)	2018–2024
Foundations for Interprofessional Collaborative Practice I/II (191U/V)	2016–2024
Pharmacotherapeutics of Pain & Addiction (685F, 291)	2016–2024
Foundations of Professional Development III (182S)	2016–2021
Introduction to Clinical Skills (289P)	2019–2021
Non-Prescription Pharmacotherapeutics II (182F/P)	2016–2020
Pharmacotherapeutics III Lab (185P)	2016–2020
Introduction to Ambulatory Care Pharmacy (291M)	2017–2018
Advanced Evidence-Based Practice (295R)	2016
Pharmacotherapeutics II Lab (175P)	2016
Research Instruction	
PhARM Program Research Assistant Internship	2020–2024
Advanced Pharmacotherapy Lab Research (PGS W385J)	2024
Advanced Pharmacotherapy Lab Research (PGS 385J)	2024
Advanced Pharmacotherapy Lab Research (PGS 285J)	2023
Research Opportunities in Pharmaceutical Science (181R)	2019–2021
Pharmacy Honors Thesis and Tutorial (489H)	2018 / 2021
Pharmacy Honors Proposal and Tutorial (288H)	2017 / 2020
Exploratory Research in Pharmacy (187R)	2017 / 2020
Pharmobility Exchange Student Research	2017–2018
Advanced Study in Pharmaceutical Research (383R)	2017
Advanced Study in Pharmaceutical Research (277K)	2016

The University of Texas at Austin Dell Medical School

Didactic Instruction	
Medical Neuroscience (MED 187MD)	2021–2023
Addiction Psychiatry Fellowship	2021
Research Instruction	
Health Leadership Apprentice Program	2018–2019

The University of Texas at Austin Steve Hicks School of Social Work

Didactic Instruction

Young People & Drugs (UGS 303) 2016–2021

University of Pittsburgh School of Medicine

Experiential Precepting

Medication Management Rotation: PGY2 Residents 2014–2015

Family Medicine Rotation: M4 Students 2013–2015

Didactic Instruction

Drug Information Resources 2015

Medical Decision-Making Seminar 2013–2015

Pharmacotherapy Core Curriculum Series 2013–2015

Policy Documents & Popular Media

Policy Document Citations

7. Teahan Á, Sharp M, Farragher A, Moloney T, Long J. [Effectiveness, safety, and cost-effectiveness of pharmacist prescribing: An evidence review](#). Dublin, Ireland: Health Research Board; 2025.
6. National Center for Health Statistics. [ICD-10 Coordination and Maintenance Committee Meeting March 20, 2024 Diagnosis Agenda](#). March 25, 2024.
5. Jacobson M, Powell D. [Price Sensitivity and Information Barriers to the Take-up of Naloxone](#). Working Paper 32029. Cambridge, MA: National Bureau of Economic Research; January 2024.
4. Smart R, Powell D, Pacula RL, Peet ED, Abouk R, Davis CS. [Investigating the Complexity of Naloxone Distribution: Which Policies Matter for Pharmacies and Potential Recipients](#). Working Paper 31142. National Bureau of Economic Research; April 2023.
3. Stein BD, Kilmer B, Taylor J, Vaiana ME, eds. [America's Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms](#). RRA604-1. Santa Monica, CA: RAND Corporation; 2023.
2. Food and Drug Administration. [Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use; Request for Comments](#). *Fed Regist*. 2022;87:68702-68713.
1. National Association of County and City Health Officials. [NACCHO Comment on Naloxone Draft Policy: Letter to Senator Baldwin](#). January 6, 2021.

Television & Radio Interviews

17. CNN Newsroom: [FDA approves overdose treatment Narcan for over-the-counter use](#). April 2, 2023.
16. KXAN Austin: [Operation Naloxone – UT Austin library offering free doses of naloxone](#). August 29, 2022.
15. KXAN Austin: [Fentanyl overdoses dropped in 4 states. These solutions are helping](#). February 18, 2022.
14. KXAN Austin: [Texas Longhorns linebacker Jake Ehlinger died of accidental overdose, family says](#). October 21, 2021.
13. KCRW Los Angeles: [Can you OD from touching fentanyl? How that myth gained a foothold among first responders](#). August 9, 2021.
12. FOX 7 Austin: [CDC report – Drug overdose deaths hit record high in 2020](#). July 15, 2021.
11. Texas Public Radio: [Drug overdoses spiked during the pandemic. What's fueling the surge?](#) January 14, 2021.

10. CBS Austin: [Texas AG's office launches website to educate, prevent opioid misuse](#). January 22, 2019.
9. CBS Austin: [Austin billionaire named in new court filing for trying to shift blame for opioid addiction](#). January 16, 2019.
8. Spectrum News Austin: [Capital Tonight – Tackling Texas' opioid epidemic](#). December 12, 2018.
7. KCBS San Francisco: [Preventing overdose deaths on campus](#). October 23, 2018.
6. NPR All Things Considered: [On college campuses, making overdose medication readily available](#). October 22, 2018.
5. Spectrum News Austin: [Lone star crisis – the opioid epidemic](#). May 16, 2018.
4. Spectrum News Austin: [Capital Tonight – Trump unveils opioid plan](#). March 19, 2018.
3. KXAN Austin: [Advocates for painkiller addicts want society to meet them halfway](#). February 18, 2018.
2. Spectrum News Austin: [In Focus – The medication used to treat overdoses](#). January 14, 2018.
1. NPR Marketplace: [Overdose prevention on campus](#). April 14, 2017.

Print Interviews

66. The Daily Texan: ['Keeping people safe' – Operation Naloxone reaches 10 years of preventing opioid overdoses](#). February 10, 2026.
65. STAT: [How Opvee, Indivior's powerful overdose antidote, went bust](#). January 29, 2026.
64. Spartan Newsroom: [Michigan had highest rate of patients unable to fill prescriptions for opioid use disorder treatment, study says](#). September 12, 2025.
63. Alcoholism & Drug Abuse Weekly: [HHS renews opioid public health emergency](#). March 24, 2025.
62. Texas Tribune: [Texas cities and counties are destroying expired Narcan. Some say it could still be used to save lives](#). October 26, 2023.
61. The Dallas Morning News: [Why a lifesaving medication to treat opioid addiction can be difficult to access](#). September 25, 2023.
60. Alcoholism & Drug Abuse Weekly: [Liquid methadone – Why it's used, and what this means for reform](#). August 28, 2023.
59. Alcoholism & Drug Abuse Weekly: [Stocking buprenorphine – The latest hitch in the MOUD field](#). May 1, 2023.
58. The Daily Texan: [FDA approves first nonprescription naloxone nasal spray for over-the-counter use](#). April 13, 2023.
57. TIME: [Over-the-counter Narcan is a great first step, but there's still work to be done](#). March 30, 2023.
56. Fox 9 Minneapolis / St. Paul: [Fentanyl misinformation – Why claims by Bloomington Police chief are part of troubling trend](#). November 16, 2022.
55. Filter: [Buprenorphine access – Telehealth revolution faces uncertain future](#). October 25, 2022.
54. Hays Free Press: [One family's story of losing a child to fentanyl](#). September 21, 2022.
53. Austin American-Statesman: [Demand so big for Austin's first Narcan vending machine, it's restocked daily](#). August 31, 2022.
52. Alcoholism & Drug Abuse Weekly: [Is extra naloxone needed for overdose reversal in the fentanyl era?](#) August 22, 2022.
51. Substance: [Walmart is rejecting prescriptions and screwing over patients with addiction](#). July 29, 2022.
50. TIME: [Fewer than half of U.S. pharmacies carry one of the most effective drugs for opioid abuse](#). June 10, 2022.

49. Alcoholism & Drug Abuse Weekly: [Buprenorphine – Pharmacies limit doses out of legal fears](#). May 23, 2022.
48. KRIS Corpus Christi: [Substance abuse symposium underway](#). March 24, 2022.
47. The Atlantic: [An anti-overdose drug is getting stronger. Maybe that's a bad thing?](#) January 14, 2022.
46. Academic Pharmacy Now: [Care interrupted](#). December 15, 2021.
45. VICE News: [No, border patrol doesn't need to be protected from fentanyl](#). September 23, 2021.
44. Washington Post: [A myth that lingers on: Casual contact with fentanyl causes overdoses](#). August 13, 2021.
43. Filter: [A guide to fentanyl touch overdoses, which do not exist](#). August 11, 2021.
42. Alcoholism & Drug Abuse Weekly: [As new administration forms, questions remain about SAMHSA and ONDCP](#). December 11, 2020.
41. Reuters Health: [After opioid overdose, poor teens rarely get addiction treatment](#). January 9, 2020.
40. Inside Higher Ed: [Wake-up call](#). November 15, 2019.
39. Popular Science: [The CDC says more prescriptions of overdose reversal drug naloxone are needed](#). August 9, 2019.
38. Pharmacy Today: Fentanyl-related deaths spike, but pharmacists can reduce associated harm. July 1, 2019.
37. Austin American-Statesman: [Drug that reverses opioid overdoses now for sale online in Texas](#). May 14, 2019.
36. Reuters Health: [Opioid addiction diagnosis and treatment climbs with Medicaid expansion](#). April 2, 2019.
35. Pharmacy Times: [Pharmacists role in providing naloxone is expanding](#). March 24, 2019.
34. Alcoholism & Drug Abuse Weekly: [Texas pharmacist works with harm reduction on STR naloxone distribution](#). March 4, 2019.
33. The Daily Texan: [New campaign to combat opioid epidemic neglects major solutions, experts say](#). January 30, 2019.
32. Austin American-Statesman: Bill would give law enforcement access to naloxone. January 20, 2019.
31. Austin American-Statesman: [Texas A&M training health students to respond to opioid overdoses](#). December 14, 2018.
30. Trusteeship Magazine: [An ounce of prevention](#). December 2018.
29. The Daily Texan: [Naloxone kits on UT-Austin campus going unused](#). October 31, 2018.
28. Pharmacy Today: Patients can get—and pharmacists can provide—naloxone at the pharmacy. Why don't they? September 2018.
27. The Daily Texan: [Students need the facts on fentanyl](#). August 3, 2018.
26. Belleville News-Democrat: [Can you really overdose from fentanyl in the air? Here's what medical experts say](#). July 13, 2018.
25. Everything Lubbock: [Texas lawmakers evaluating drug overdose "Good Samaritan" laws](#). June 26, 2018.
24. Austin American-Statesman: ["We are not immune" – how the opioid crisis is hitting Central Texas](#). June 7, 2018.
23. The Daily Texan: [Nation's top doctor advises Americans carry life-saving opioid overdose reversal drug](#). April 11, 2018.
22. The Daily Texan: [UT students turning to Adderall for academic success](#). March 25, 2018.
21. Drug Topics: [Four ways pharmacists are fighting opioid abuse](#). March 14, 2018.
20. Houston Chronicle: [Texas college students, fearing opioid deaths, teach each other to reverse overdoses](#). March 4, 2018.

19. The Daily Texan: [Opioid crisis continues despite declaration as public health emergency](#). February 19, 2018.
18. Alcalde: [How Texas is trying to stay ahead of the opioid epidemic](#). January 1, 2018.
17. The Daily Texan: [UT Wellness Network hosts first drug take back event](#). November 30, 2017.
16. The Daily Texan: [Scale of opioid epidemic in Texas likely obscured by bad data, experts say](#). November 21, 2017.
15. The Daily Texan: [Social work students receive opioid overdose response training](#). November 13, 2017.
14. The Daily Texan: [Center for Health Communication receives contract to promote Texas' prescription monitoring program](#). October 31, 2017.
13. The Daily Texan: [Trump declares opioid crisis a public health emergency](#). October 30, 2017.
12. The Daily Texan: [Operation Naloxone given grant to service opioid addiction](#). October 6, 2017.
11. The Daily Texan: [Partners of School of Social Work distribute life-saving medication to Harvey-affected areas](#). October 6, 2017.
10. UT News: [This is why the opioid crisis is as dangerous as a terrorist attack](#). September 26, 2017.
9. The Utopian: [Minimizing harm](#). September 21, 2017.
8. The Daily Texan: [UT professionals unite to tackle drug abuse](#). September 7, 2017.
7. WalletHub: [Drug use by state – 2017's problem areas](#). May 15, 2017.
6. The Daily Texan: [Brave New Books advertises kratom drug for sale](#). January 24, 2017.
5. The Daily Texan: [College of Pharmacy combats opioid overdoses with campus campaign](#). October 4, 2016.
4. The Daily Texan: [International Overdose Awareness Day recognized by students and faculty at Capitol](#). September 2, 2016.
3. Dallas Observer: [Opioid overdose drug now available without a prescription in Texas](#). June 24, 2016.
2. Texas Pharmacy Association: [Standing order announced expanding pharmacists' ability to provide naloxone](#). June 16, 2016.
1. Drug Topics: [Pharmacist provider status gains traction](#). March 10, 2015.

Television, Radio, & Print Mentions

66. GlobeNewswire: Foundation for Opioid Response Efforts and the Yale Program in Addiction Medicine establish the National Methadone Access and Quality Commission. <https://bit.ly/3M1Jbpx>. January 28, 2026.
65. Stateline: Telemedicine patients with opioid use disorder struggle to fill prescriptions. <http://bit.ly/3I04oOL>. August 22, 2025.
64. MedPage Today: Pharmacy barriers can hinder telehealth treatment for opioid addictions. <http://bit.ly/46EIVFw>. August 18, 2025.
63. Pennsylvania Department of Health and Pennsylvania Department of Drug and Alcohol Programs: Compassionate overdose response. <http://bit.ly/47r4etO>. June 2025.
62. Filter: Secret shoppers struggle to buy naloxone, syringes at Texas pharmacies. <https://bit.ly/3GRVckC>. May 5, 2025.
61. NPR: Misinformation about fentanyl exposure threatens to undermine overdose response. <http://bit.ly/3VPCtnE>. April 3, 2025.
60. The National Tribune: 'There has never been a more dangerous time to take drugs' – The rising global threat of nitazenes and synthetic opioids. <http://bit.ly/3VP7k3N>. February 8, 2025.
59. Salon: Surviving an overdose can be excruciating – New research suggests it doesn't have to be. <http://bit.ly/3I3RUFQ>. February 6, 2025.

58. The Guardian: New class of opioids that may be more potent than fentanyl emerges globally. <https://bit.ly/3XDgscu>. September 25, 2024.
57. KXAN Austin: Austin, Travis County leaders discuss distributing Narcan kits. <https://bit.ly/3K0Vm19>. May 13, 2024.
56. Slate: What's going on with tranq? <https://bit.ly/3QOVVPw>. May 12, 2024.
55. The Daily Texan: White House recognizes UT's opioid overdose prevention program. <https://bit.ly/3TxZSZw>. March 22, 2024.
54. White House: Biden-Harris Administration launches the White House Challenge to Save Lives from Overdose. <https://bit.ly/3x23Kdp>. March 13, 2024.
53. Texas Tribune: Texas A&M suspended professor accused of criticizing Lt. Gov. Dan Patrick in lecture. <https://bit.ly/3Qbg3f2>. July 25, 2023.
52. RTI International: Maximizing Partnerships to Address the Overdose Crisis in Texas. <http://bit.ly/3ZUy6HA>. April 3, 2023.
51. New York Times: Over-the-counter Narcan could save more lives. But price and stigma are obstacles. <http://bit.ly/3nz6iuQ>. March 28, 2023.
50. Politico: Biden's next battle in his opioids fight – His own bureaucracy. <http://bit.ly/3L3dE3H>. March 8, 2023.
49. CNN: FDA considers making Narcan opioid overdose antidote available without prescription. <http://bit.ly/4nT81Fx>. February 15, 2023.
48. CNN: FDA advisers vote in favor of making opioid overdose antidote available over the counter. <http://bit.ly/4pqDboY>. February 15, 2023.
47. New York Post: Narcan overdose antidote close to being sold over the counter – FDA meeting. <http://bit.ly/41U6KVY>. February 15, 2023.
46. Quartz: Rainbow fentanyl is a war on drugs tactic. <https://bit.ly/3Md7TPe>. October 5, 2022.
45. Austin Chronicle: Opinion – How to stop drug overdoses in Austin. <https://bit.ly/3oTm2WX>. August 5, 2022.
44. Tallahassee Democrat: Drug user advocates worry more criminalization of polluted drug supply will cause overdoses. <https://bit.ly/3IKCF5y>. May 24, 2022.
43. KXAN Austin: University of Texas at Austin has naloxone available for free. <https://bit.ly/36UAecX>. April 18, 2022.
42. Spectrum News Austin: New UT program makes Narcan accessible on campus. <https://bit.ly/3uW4qww>. April 5, 2022.
41. The Daily Texan: Free opioid overdose-reversing drug now accessible in some UT libraries. <https://bit.ly/3ueHklp>. April 5, 2022.
40. ABC News Austin: What is Xylazine? A look at the veterinary tranquilizer being found in counterfeit pills. <https://bit.ly/3NNeSgY>. March 31, 2022.
39. Corpus Christi Caller Times: Here's why the Texas Substance Use Symposium is coming to Corpus Christi. <https://bit.ly/3IEoUOV>. March 23, 2022.
38. El Paso Matters: UTEP campus police do not carry Narcan, despite UT System approval. <https://bit.ly/37VD2r2>. March 21, 2022.
37. Fox News Austin: Naloxone available for free to UT Austin students, staff. <https://bit.ly/3DTFqdd>. March 17, 2022.
36. ABC News Austin: University of Texas no providing Narcan to students, staff and faculty for free. <https://bit.ly/3DKGCQb>. March 17, 2022.
35. Texas Pharmacy: Gaps in support for people with opioid use disorder – An opportunity for advocacy. <https://bit.ly/3gpArGo>. February 4, 2022.
34. STAT News: How much naloxone is needed to reverse an opioid overdose? New high-dose treatments are raising questions. <https://bit.ly/31SMrg0>. December 15, 2021.
33. UT Dell Medical School: First digital platform to track and prevent drug overdoses in Texas launches. <https://bit.ly/31xLg5h>. December 2, 2021.

32. The Daily Texan: As fentanyl-related overdoses increase, UT provides support to students struggling with addiction. <https://bit.ly/3CenkA7>. November 10, 2021.
31. VICE News: Did Astroworld attendees get stabbed with drugs? Not likely. <https://bit.ly/3kdwBCv>. November 8, 2021.
30. Defector: The myth of cops overdosing from touching fentanyl persists for a reason. <https://bit.ly/2XocsRF>. August 12, 2021.
29. San Diego Union Tribune: Exaggerating fentanyl's danger a bad move on San Diego County sheriff's part. <https://bit.ly/3jSktFV>. August 11, 2021.
28. The Wrap: CNN deletes debunked fentanyl 'overdose' story amid outcry from physicians group. <https://bit.ly/3xEt9EO>. August 11, 2021.
27. AP: California sheriff – He, not doctor, diagnosed video overdose. <https://bit.ly/3xGdzIR>. August 10, 2021.
26. CBS News: Experts question video of deputy who purportedly “almost died” from substance said to be fentanyl. <https://cbsn.ws/2VJdOG6>. August 10, 2021.
25. San Diego Union Tribune: Sheriff 'shocked' by pushback from medical experts over fentanyl video. <https://bit.ly/3AoYWv8>. August 9, 2021.
24. Filter: The naloxone arms race is headed nowhere good. <https://bit.ly/2SnbC5x>. June 23, 2021.
23. San Luis Obispo Tribune: 'Every second counts.' Why Cal Poly educators are pushing to get life-saving drug on campus. <https://bit.ly/3iw0HRI>. June 8, 2021.
22. Tribeza: Austin Under 40's 2021 nominees announced. <https://bit.ly/3tifEdu>. May 2021.
21. Austin Chronicle: Drug use is the reality for millions. There are ways to make it safer. <https://bit.ly/3mYXBUT>. December 25, 2020.
20. Narcotica Podcast: Episode 46 – Behind the pharmacists' counter. <http://bit.ly/3rGLz5a>. August 17, 2020.
19. UT Center for Health IPE: Interprofessional practice in action. <https://bit.ly/2Xlq24F>. May 21, 2020.
18. UT Austin: Light the tower – World changing Longhorns. <https://bit.ly/3fH3TWx>. May 11, 2020.
17. Tribeza: Austin Under 40 Awards set to honor 2020 finalists. <https://bit.ly/3jn1FNz>. March 5, 2020.
16. Spectrum News Austin: Capital Tonight – Texas leads way in online Narcan sales, other states following suit. <http://bit.ly/2NHj3z7>. November 11, 2019.
15. The Daily Texan: UT's Drug-Free Schools Act review recommends formation of committee to evaluate substance use. <http://bit.ly/2odgmLZ>. October 18, 2019.
14. Spectrum News Austin: Pharmacy students hold workshop on opioid overdoses. <http://bit.ly/2IGIVMe>. February 28, 2019.
13. UT Center for Health Communication: Operation Naloxone: Overdose prevention service learning for student pharmacists. <http://bit.ly/2AL0a7R>. January 2019.
12. Texas A&M Today: Training to reverse opioid overdoses. <http://bit.ly/2CVio7Y>. December 11, 2018.
11. Filter: Public health experts call for retraction of Brookings Institution opioid “research roundup”. <http://bit.ly/2Qu3s92>. December 11, 2018.
10. San Antonio Express-News: \$11M grant to combat opioid crisis could put naloxone in hands of more first responders, civilians. <https://bit.ly/3fCHCsr>. August 3, 2018.
9. Vox: Needle exchanges have been proved to work against opioid addiction. They're banned in 15 states. <https://bit.ly/2uA31NN>. June 22, 2018.
8. The Daily Texan: Student committee's prescription drug take back day combats nation-wide drug crisis. <https://bit.ly/2Htmvfo>. April 25, 2018.
7. KXAN Austin: UT looks to take on youth addiction with 'Pop-Up Institute'. <https://bit.ly/2r1xlyc>. April 17, 2018.

6. Digital Pharmacist: Naloxone and the opioid epidemic. <http://bit.ly/2iK1p0G>. August 24, 2017.
5. The Daily Texan: Naloxone – a miracle medication for the opioid epidemic. <http://bit.ly/2yctxAl>. July 14, 2017.
4. Longhorn Pharmacy Focus: Operation Naloxone. <http://bit.ly/2iQpr7r>. Spring 2017.
3. Orange Magazine: College of Pharmacy students discuss opioid overdoses. <http://bit.ly/2ydd0wc>. April 7, 2017.
2. ACCP StuNews: Student Chapter Spotlight – The University of Texas at Austin College of Pharmacy. <http://bit.ly/2zmr4W>. January 2017.
1. The Daily Texan: Co-op residents prepare for overdose emergencies by participating in Operation Naloxone. <http://bit.ly/2yUTx2W>. September 27, 2016.